The Role and Impact of Non-driver Gene Mutations in Myelofibrosis Valentina Boldrini, Paola Guglielmelli, Alessandro M. Vannucchi Current Hematologic Malignancy Reports, 2026 Purpose of the Review Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis and potential progression to a blast phase. This review provides a comprehensive overview of the current molecular landscape of MF beyond canonical driver mutations ( JAK2 , MPL or CALR) , emphasizing insights gained from murine models that served as valuable tools for understanding disease mechanisms. Recent Findings High-throughput next-generation sequencing (NGS) has markedly enhanced our understanding of the molecular basis of MF, identifying numerous mutations beyond the canonical driver genes JAK2 , MPL , and CALR , which are present in about 80% of patients. Additional mutations affect genes involved in DNA methylation ( TET2 , DNMT3A , IDH1 , IDH2 ), histone modification ( ASXL1 , EZH2 ), mRNA splicing ( SF3B1 , SRSF2 , U2AF1 , ZRSR2 ), signaling pathways ( CBL , NRAS , KRAS ), and key transcription factors ( RUNX1 , NFE2 , TP53 ). The presence and combination of these alterations influence clinical presentation, prognosis, and therapeutic response. Summary This review offers an updated synthesis of the evolving molecular landscape of MF, highlighting how the intricate interplay among genetic alterations has deepened our understanding of disease heterogeneity, allowing refined risk stratification and therapeutic planning. Advances emerging from molecular research and experimental models are progressively translating into clinical practice, promoting more personalized and targeted approaches to the management of MF.
Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus Maria D’Amato, Chiara Maria Rapolla, Edoardo Benedetti, Monica Bocchia, Enrico Capochiani, Gabriella Carlomagno, Sara Ciofini, Roberta Giachetti, Giacomo Maestrini, Sabrina Moretti, Daniela Nasso, Giulia Papini, Maria Teresa Pirrotta, Federico Simonetti, Simone Santini, Alessandro Vannucchi, Sara Galimberti, Alessandro Sanna Clinical and Experimental Medicine, 2026 Management of chronic lymphocytic leukemia/ small lymphocytic lymphoma. (CLL/SLL) has undergone a significant paradigm shift, with chemo immunotherapy being virtually abandoned in favor of targeted agents. A panel of CLL/SLL experts from Tuscany proposes an updated real-life diagnostic and therapeutic approach that integrates genomic and somatic prognostic factors into routine risk stratification and treatment decisions. While the safety and efficacy of new agents are well-established in both clinical trials and real-world series, the rapid introduction of second-generation BTK inhibitors and BCL-2 antagonists necessitates a uniform and shared approach for daily clinical practice. This updated consensus reinforces the essential role of FISH for 17p deletion and TP53 mutational status before every treatment line, while IGHV mutation status should be performed for initial risk assessment. Reflecting current evidence, the proposal emphasizes a comprehensive pretreatment workup, with a particular focus on cardio-oncological screening and monitoring according to recent ESC guidelines to mitigate risks associated with BTKIs. The consensus reaffirms abdominal and superficial lymph node ultrasound as the gold standard radiological investigation for both diagnosis and response evaluation in CLL, offering a practical and radiation-free tool for longitudinal monitoring. Treatment selection is tailored based on age, genetic risk, and comorbidities, prioritizing zanubrutinib, acalabrutinib, and venetoclax-based regimens to prevent unnecessary toxicities. Furthermore, the consensus addresses the management of high-risk scenarios, including Richter transformation and the emerging role of pirtobrutinib and BTK degraders. By combining the latest clinical evidence with extensive daily experience, this updated Tuscany consensus provides a practical framework for optimized, personalized management of CLL/SLL patients in the modern therapeutic era.
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia Niccolò Bartalucci, Francesco Mannelli, Danilo Tarantino, Alessio Enderti, Simone Romagnoli, Daniele Colazzo, Barbara Scappini, Giacomo Gianfaldoni, Matteo Piccini, Leonardo Signori, Fiorenza Irushani, Silvia Salmoiraghi, Tiziana Ottone, Alfonso Piciocchi, Margherita Vannucchi, Maria Chiara Siciliano, Roberto Boccacci, Silvia Orsi, Alessia Civini, Paola Fazi, Raffaella Santi, Marco Vignetti, Stefania Bortoluzzi, Alberto Bosi, Adriano Venditti, Alessandro Rambaldi, Maria Teresa Voso, Paola Guglielmelli, Alessandro M. Vannucchi Blood Cancer Journal, 2026 Cytogenetic and genomic profiling of acute myeloid leukemia (AML) guides personalized treatment according to ELN2022 recommendations. However, marked outcome variability persists among cytogenetically normal (CN-) patients, representing an unmet clinical need. We used long-read whole-genome sequencing to interrogate the prognostic significance of structural variations (SVs) in a prospective cohort of 162 intensively treated CN-AML patients. After stringent filtering, we identified 5 somatic SVs associated with shorter overall survival (OS) (HR:4.18, p < 0.001) and event-free survival (EFS) (HR:3.59, p < 0.001) in 13% of the patients. Results were validated in a real-world cohort of 149 CN-AML, using target assays. These high-risk SVs (HRVs) operationally defined a “very high-risk” category in the framework of ELN2022, overall resulting in more accurate OS prediction. HRVs were independent of most frequent mutations, particularly FLT3ITD and NPM1mut. Among the latter patients, HRVs independently predicted shorter OS (8.2 months versus not-reached; p < 0.001), EFS (3.5 versus 25.7 months; p < 0.001), and lower complete response rates (66.7% versus 90.1%; p < 0.005). Finally, we provided evidence of transcriptional deregulation of SV-related genes in primary samples and engineered cell models. Current findings support the value of SVs for refining risk stratification in CN-AML, by identifying patients at exceedingly dismal outcome who might benefit from personalized approaches.
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities Giuseppe G. Loscocco, Fnu Aperna, Moazah Iftikhar, Priyansh Faldu, Masooma S. Rana, Animesh Pardanani, Paola Guglielmelli, Alessandro M. Vannucchi, Naseema Gangat, Ayalew Tefferi American Journal of Hematology, 2026 Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic Philadelphia chromosome negative myeloproliferative neoplasms (MPN) characterized by clonal hematopoiesis, thrombotic risk, and variable disease evolution [1, 2]. Increasing evidence supports a role for immune dysregulation and inflammatory pathways in disease development and clinical heterogeneity, although their clinical implications remain incompletely defined [3]. Epidemiological studies have reported an association between prior autoimmune diseases and an increased risk of developing MPN [4]. Autoimmune or inflammatory diseases (AID) have also been described in approximately 6%–8% of patients with MPN, with heterogeneous effects on clinical features and survival across cohorts [5, 6]. However, the clinical burden of AID in patients specifically affected by PV and ET, particularly concerning disease outcomes and comorbidity profiles, remains poorly defined. We therefore evaluated the prevalence of AID in a large cohort of patients with PV and ET and assessed their association with disease outcomes and comorbidities. Institutional review board approval was obtained from the Mayo Clinic, Rochester, MN, USA, for retrospective data collection in accordance with the Declaration of Helsinki. The study included consecutive patients with PV and ET evaluated between 1970 and 2024 and diagnosed according to the 2022 International Consensus Classification criteria [7]. AID were defined according to established disease-specific clinical and serologic criteria. Clinical and laboratory variables were collected at diagnosis or first referral. Thrombotic events were confirmed by imaging studies and classified as arterial or venous; AID, cancers, and thrombotic events were categorized as occurring before/at or after MPN diagnosis using a ≥ 3 month interval. Overall survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Competing-risk analyses were performed for thrombosis, leukemic transformation, myelofibrosis progression, second cancer, and incident AID using Fine–Gray regression models. Categorical variables were compared using the chi-square or Fisher's exact test, and continuous variables using the Mann–Whitney U test. Statistical analyses were performed using SPSS, JMP, and R software. Among 1968 patients with polycythemia vera (PV) or essential thrombocythemia (ET), 121 (6%) had a history of AID before/at the time of MPN diagnosis (Table 1). Compared with patients without AID, those with prior AID were older (median age 62 vs. 60 years, p = 0.016), more frequently female (69% vs. 55%, p = 0.002), and less likely to have PV (40% vs. 52%, p = 0.011). Hemoglobin levels were significantly lower in patients with AID (median 14.9 vs. 16 g/dL; p = 0.003), while platelet and leukocyte counts were similar between groups. A history of venous thrombosis at or prior to diagnosis was more frequent among patients with AID (18% vs. 12%, p = 0.046), whereas arterial thrombosis rates were comparable. Patients with previous AID more frequently had a history of other malignancies before/at MPN diagnosis (25% vs. 14%, p = 0.001), including when non-melanoma skin cancers (NMSC) were excluded (18% vs. 10%, p = 0.006). Additionally, the occurrence of subsequent AID during follow-up was more common among patients with prior AID (6% vs. 2%, p = 0.005). Among the 121 patients with AID before/at MPN diagnosis, 48 (40%) had PV and 73 (60%) had ET. Patients with PV were older (median 65 vs. 59 years, p = 0.043) and females were more common among ET cases (78% vs. 56%, p = 0.011). As expected, PV patients displayed higher hemoglobin levels, leukocyte counts, and neutrophil counts, while ET patients had higher platelet counts. Fibrotic progression was more frequent among PV cases (17% vs. 3%, p = 0.006), whereas leukemic transformation rates were low and comparable (Table S1). The spectrum of AID observed before/at and after MPN diagnosis is detailed in Figure 1A. The most frequently observed conditions included autoimmune dysthyroidism, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and polymyalgia rheumatica. Kaplan–Meier analysis showed no significant difference in survival between patients with and without prior AID (log-rank p = 0.09, Figure 1B). In univariate analysis, prior AID showed a borderline association with inferior OS (HR 1.36, 95% CI 0.96–1.94, p = 0.087). After adjustment for sex, age, PV phenotype, and JAK2 mutation status, the association remained borderline and moved closer to statistical significance (HR 1.42, p = 0.054). Male sex (HR 1.50, 95% CI 1.27–1.77, p < 0.001) and increasing age (per 10 years, HR 2.43, 95% CI 2.25–2.62, p < 0.001) were independently associated with inferior survival, whereas PV (HR 1.15, p = 0.16) and JAK2 mutation status (HR 1.14, p = 0.34) were not significantly associated. To explore potential heterogeneity across AID, patients with prior AID were further stratified into two predefined categories based on the predominant clinical phenotype and anticipated degree of systemic inflammatory burden, distinguishing inflammatory arthritis, vasculitis, or unclassified AID from predominantly organ-specific, connective tissue, or inflammatory dermatosis conditions (Figure S1). In univariate analysis, patients with inflammatory arthritis, vasculitis, or unclassified AID exhibited significantly inferior survival compared with patients without AID (HR 1.89, 95% CI 1.13–3.16; p = 0.015), whereas those with organ-specific, connective tissue, or inflammatory dermatosis AID showed no significant difference (HR 1.10, 95% CI 0.69–1.77; p = 0.679). After multivariable adjustment, inflammatory arthritis/vasculitis/unclassified AID remained significantly associated with inferior survival (HR 1.64, 95% CI 1.01–2.70; p = 0.040), whereas organ-specific/connective tissue/inflammatory dermatosis AID showed no significant association (HR 1.29, 95% CI 0.80–2.08; p = 0.294). The cumulative incidence of major clinical outcomes after MPN diagnosis was assessed using competing-risk analysis (Figure S2). Prior AID was not significantly associated with MF progression (Gray test p = 0.20), AML progression (p = 0.52), venous (p = 0.49), or arterial thrombosis (p = 0.86). Conversely, a history of AID was associated with an increased risk of SC (Gray test p < 0.001, sHR 1.57, p = 0.015, Figure 2A). This association remained significant after excluding non-melanoma skin cancers (NMSC) (sHR 1.70, p = 0.022), whereas after excluding both NMSC and hematologic malignancies, only a non-significant trend was observed (sHR 1.52, p = 0.12). In the multivariable model including all cancers, prior AID was not independently associated with SC risk (sHR 1.31, 95% CI 0.88–1.96, p = 0.183) after adjustment for sex, age, PV versus ET, JAK2 mutation status, prior cancer history, hyperlipidemia, hypertension, and arterial thrombosis. Of interest, after exclusion of NMSC, prior AID showed a trend toward increased SC risk (sHR 1.50, 95% CI 0.93–2.42, p = 0.094). This association was no longer observed in the most restrictive model excluding both NMSC and hematologic malignancies (sHR 1.35, 95% CI 0.79–2.32, p = 0.276). The occurrence of incident AID after MPN diagnosis was subsequently analyzed using competing-risk methods. The cumulative incidence of AID was significantly higher among patients with prior AID compared with those without (Gray test p < 0.001, Figure 2B). In univariate analysis, prior AID (sHR 3.89, p = 0.001) and female sex (sHR 2.63, p = 0.007) were significantly associated with an increased risk of incident AID. Hypertension showed a borderline association (sHR 1.74; p = 0.095), whereas no other clinical, hematologic, or molecular variables were significantly associated (Table S2). In the multivariable model (Figure 2C), prior AID (sHR 3.03, p = 0.012), female sex (sHR 2.39, p = 0.015), and hypertension (sHR 2.18, p = 0.024) remained independently associated with an increased risk of incident AID. In this large cohort of patients with PV and ET, AID were identified in 6% of cases and were associated with a distinct clinical and comorbidity profile. Patients with prior AID were more frequently female, slightly older, and more likely to have a history of venous thrombosis and prior malignancy. These findings are consistent with previous epidemiologic studies supporting shared inflammatory and immune-mediated mechanisms across AID and myeloid neoplasia, as well as the increased risk of MPN development among patients with pre-existing AID [4, 6, 8]. Although prior AID was not significantly associated with fibrotic or leukemic progression, nor with arterial or venous thrombosis during follow-up, a borderline association with inferior survival was observed and persisted after multivariable adjustment. Exploratory analyses highlighted heterogeneity across autoimmune phenotypes, with selected AID categories demonstrating a sustained association with inferior survival [9]. Collectively, these findings support the concept that immune dysregulation and chronic inflammatory burden contribute to disease heterogeneity in MPN, influencing long-term outcomes beyond classical disease-related risk factors [3]. A history of AID was associated with an increased risk of SC in unadjusted analyses, particularly after exclusion of NMSC, although this association was attenuated after multivariable adjustment. This finding suggests that part of the observed risk may be explained by coexisting clinical factors, including prior malignancy history and cardiometabolic comorbidities, while remaining consistent with prior observations linking chronic immune dysregulation with carcinogenesis across multiple disease settings [5, 10-12]. A particularly relevant observation was the significantly increased risk of incident AID after MPN diagnosis among patients with prior AID, independent of sex, age, and hypertension. This finding aligns with the well-recognized phenomenon of polyautoimmunity, whereby individuals with one autoimmune disease have an increased risk of developing additional immune-mediated conditions over time [13, 14]. Several limitations should be acknowledged. The retrospective design introduces potential selection and ascertainment biases, and the relatively low number of specific outcomes may have limited statistical power in subgroup analyses. In addition, treatment heterogeneity across the long study period was not specifically accounted for and may have influenced clinical outcomes. Furthermore, the intrinsic heterogeneity of AID, encompassing conditions with distinct pathophysiologic mechanisms and clinical trajectories, limited the ability to evaluate outcomes for individual AID entities and required grouping into broader categories, which may have diluted subtype-specific associations. Despite these limitations, the large sample size, extended follow-up, and use of competing-risk methodology strengthen the robustness of the findings. G.G.L., N.G., and A.T. conceived and designed the study. G.G.L., F.A., M.I., P.F., M.S.R., and N.G. collected the data. G.G.L. performed statistical analyses. G.G.L. drafted the manuscript. P.G., A.M.V., A.P., N.G., and A.T. reviewed and edited the manuscript. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. TABLE S1: Clinical, laboratory, and genetic characteristics at diagnosis and during follow-up in 121 patients with autoimmune or inflammatory disease before/at MPN diagnosis, stratified by polycythemia vera and essential thrombocythemia. TABLE S2: Univariate Fine–Gray regression analysis for risk of incident autoimmune or inflammatory diseases (AID) after MPN diagnosis. FIGURE S1: Overall survival according to autoimmune or inflammatory disease (AID) category. Kaplan–Meier curves comparing overall survival among patients with arthritis/vasculitis/unclassified AID, organ-specific/connective tissue disease (CTD)/dermatosis, and patients without prior AID. FIGURE S2: Cumulative incidence of major disease outcomes according to prior autoimmune or inflammatory disease (AID). Cumulative incidence curves comparing patients with prior AID versus no prior AID for (A) myelofibrosis (MF) progression, (B) acute myeloid leukemia (AML) progression, (C) venous thrombosis, and (D) arterial thrombosis. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia Matteo Piccini, Naseema Gangat, Francesco Mannelli, Barbara Scappini, Gaia Ciolli, Francesca Crupi, Andrea Pasquini, Jessica Caroprese, Giorgio Cannetti, Chiara Lucarelli, Silvia Querceto, Giada Rotunno, Fabiana Pancani, Niccolò Bartalucci, Paola Guglielmelli, Ayalew Tefferi, Alessandro Maria Vannucchi American Journal of Hematology, 2026 NPM1 mutations occur in ~30% of acute myeloid leukemia (AML) [1] and define a distinct entity according on current WHO and ICC classification [2, 3]. NPM1mut AML shows heterogeneous clinical behavior: some patients respond well to chemotherapy with rapid measurable residual disease (MRD) clearance, while others experience primary refractoriness or early relapse. Co-mutations, particularly FLT3-ITD, contribute to this variability [4]. While first-line treatment of NPM1mut AML is well established [1], optimal management of relapsed/refractory (R/R) disease remains uncertain. Furthermore, in case of primary refractory or early relapsing patients, chemoresistance represents an issue [5]. For patients treated with curative intent, salvage chemotherapy followed by allogeneic stem cell transplantation (ASCT) is standard approach, although such regimens are burdened by toxicities that delay or prevent ASCT in some cases. In elderly and HSCT ineligible patients, therapeutic options are limited. Recently, favorable toxicity profile and efficacy of venetoclax (VEN) in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) in NPM1mut AML was reported in first line [6, 7] and the R/R setting [8-10]. Moreover, considering the evolving therapeutic scenario, the role of MRD-directed intervention in NPM1mut AML, based on early detection of impending relapse at the molecular level, is unclear [11]. We retrospectively analyzed 58 adult patients with R/R or MRD-positive NPM1mut AML treated with VEN-based approaches at Careggi University Hospital, Florence (Italy) (n = 28) and Mayo Clinic, Rochester, Minnesota (US) (n = 30) between 2018 and 2025. Median age was 61.5 years (26–83); 31/58 (53.4%) patients were older than 60 years. Median follow-up duration was 26.2 months. Most patients (n = 43, 74%) were treated for relapsed disease (1st relapse, n = 35; subsequent relapse, n = 8), that in most cases occurred after CR of short duration (< 6 months, n = 27; 6–12 months, n = 9; > 12 months, n = 5; unknown, n = 2). Three patients were primary refractory. Twelve patients received VEN-based treatment as an MRD-directed approach (MRD persistence after frontline chemotherapy, n = 8; MRD relapse, n = 4). Overall, 37 patients (64%) were treated with intention-to-transplant (ITT); ultimately, 29/37 patients (78%) were able to proceed to ASCT. VEN-based treatments were mainly represented by VEN combined with HMA (n = 47/58; 81%; azacitidine, n = 30; decitabine, n = 17); other combinations including FLT3 inhibitors (FLT3i), menin inhibitors, or intensive chemotherapy. Full details of patients' characteristics and treatment regimens can be found in Table S1. Most frequently detected co-mutations were FLT3-ITDs (n = 24; 41%; median allelic ratio 0.425 (0.002–1.500)), DNMT3A (n = 23; 39%), IDH1 and IDH2 (n = 17; 31%), RAS pathway (n = 14; 24%), and FLT3-TKD (n = 6; 10%) (Figure 1 and Table S2). A total of 282 cycles were administered (with hospitalization, n = 46; 16.3%); median cycle number per patient was 4 for non-ASCT patients and 3 for HSCT recipients. Reasons for treatment discontinuation were ASCT (n = 22), treatment failure (n = 20), excessive myelotoxicity (n = 5), unknown reasons (n = 4), medical decision (n = 3), infection (n = 1), death due to unrelated cause (n = 1). At the time of data cut-off, two patients were still receiving treatment. Overt R/R cohort: composite CR rate (CCR; CR + CR with incomplete counts recovery) was 65.2% (30/46), with 17/46 (36.9%) patients achieving CR and 13/46 (28.3%) CRi status. About 70% of complete responders achieved MRD negativity in bone marrow (BM) and/or peripheral blood (PB) by RT-qPCR (or flow cytometry, in case of noncanonical mutant NPM1 transcripts). Best response occurred early during treatment (cycle 1, n = 20; cycle 2, n = 4; cycle 3, 4, and 6, n = 1; unknown, n = 3). No genetic biomarker (including aberrant karyotype, FLT3-ITD status, IDH1/2 status, RAS pathway mutations) or prior exposure to HMA or FLT3i influenced CR probability (Table S3). Patients with FLT3 mutation (ITD or TKD) had a CCR of 63.6% (14/22; CR, n = 6; CRi, n = 8); restricting the analysis to FLT3-ITD cases, CCR was 55.5% (10/18; CR, n = 2/10; CRi, n = 8/10). Prior FLT3i exposure did not reduce CCR in FLT3-mutated patients. Eighteen of 25 (72%) patients treated with ITT were able to proceed to ASCT. Median OS and EFS was 20.7 and 13 months, respectively (Figures 2 and 3). IDH1 or IDH2 mutation was associated with longer, though not statistically significant, EFS (45.7 vs. 9.7 months, p = 0.137) and OS (24.5 vs. 9.5 months; p = 0.064). Conversely, FLT3-ITD positivity was associated with shorter EFS (9.5 vs. 13.9 months) and OS (9.5 vs. 24.5 months). Patients undergoing had significantly longer EFS (26.8 vs. 5.7 months; p = 0.048) and OS (median not reached vs. 9.5 months; p = 0.013). A survival plateau for both EFS and OS was observed, with seven patients experiencing long-term survival at data cut (five off treatment). In multivariate analysis, both IDH1/2 mutation and ASCT were independently associated with improved outcomes. IDH1/2 mutation was associated with a > three-fold reduction in risk of death (OS: HR 0.324; 95% CI, 0.108–0.968; p = 0.043) and a nonsignificant reduction in event risk (EFS: HR 0.400; 95% CI, 0.146–1.097; p = 0.075). ASCT was significantly associated with improved OS (HR: 0.267; 95% CI: 0.103–0.690; p = 0.006) and EFS (HR: 0.371; 95% CI: 0.103–0.885; p = 0.025) (Table S4). MRD relapse/persistence cohort: All patients achieved complete MRD clearance by RT-qPCR, including 7 with FLT3 mutations (FLT3-TKD, n = 1; FLT3-ITD, n = 6). Best response occurred at cycle 1 in 5 patients, cycle 2 in 3, cycle 3 in 3, and cycle 4 in 1. All patients were successfully bridged to ASCT, except for a 57-year-old woman diagnosed with end-stage cholangiocarcinoma (Table S3). Median OS and EFS were not reached (Figure 3), and most OS events were due to transplant-related mortality. The safety profile was consistent with previous reports, with no treatment-related deaths. Nonhematologic adverse events are reported in Table S5. Notably, in the MRD relapse/persistence cohort, VEN-based regimens (VEN-AZA, n = 9; VEN-AZA + ziftomenib, n = 2; VEN + gilteritinib, n = 1) were particularly well tolerated, with cytopenias (mainly neutropenia) as the most frequent treatment-related AE and only one case of G3 febrile neutropenia. To our knowledge, this represents one of the largest series evaluating outcomes of R/R and MRD positive NPM1mut AML patients treated with VEN-based combinations. The observed CCR rate is comparable to that reported for conventional salvage regimens in R/R AML patients [12], including NPM1mut cases, despite most patients in our cohort would being ineligible for intensive chemotherapy due to age or comorbidities and having short prior CR duration, a setting typically associated with poor outcomes. Although the study was not powered to assess the impact of co-mutations on CR achievement and survival, improved outcomes were observed in patients with IDH1 or IDH2 mutations, consistent with previous reports [7, 9, 10]. In FLT3mut patients, while FLT3 inhibitor-based regimens remain preferred, VEN-based approaches may represent a potential option. Notably, patients treated for MRD relapse or persistence achieved high MRD clearance and favorable survival. The tolerability and activity of VEN-based regimens support their potential role in MRD-directed therapy, currently being investigated in a phase II GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) trial (NCT04867928). The favorable toxicity profile of VEN-based regimens may offer an advantage over conventional salvage chemotherapy, particularly as bridge-to-transplant in R/R NPM1mut AML. Interestingly, the durable CRs were observed in some patients even without ASCT, warranting further investigation. This work received funding from “Fondo Zottola”, University of Florence. This study was reviewed and approved by the Institutional Review Board (Comitato Etico Area Vasta Centro—CEAVC). Written informed consent was obtained by patients according to the Declaration of Helsinki. M.P.: Speaker bureau AbbVie Pharmaceuticals, Astellas, Astrazeneca, SERB, Amgen, Incyte. N.G.: Advisory Board for DISC Medicine and Agios. F.M.: Speaker bureau Blueprint, Novartis, Abbvie, Servier, GSK, Astellas. A.M.V.: honoraria from AbbVie, Novartis, Blueprint, GSK. The data that support the findings of this study are available from the corresponding author upon reasonable request. Table S1: Clinical and demographic characteristics of the study population. CR, complete remission; FLT3i, FLT3 inhibitor; HSCT, hematopoietic stem cell transplantation; ITD, internal tandem duplication; ITT, intention-to-transplant; MRD, minimal residual disease; TKD, tyrosine kinase domain; VEN, venetoclax. Table S2: Cytogenetic and molecular characteristics of the whole patient population. Full details regarding co-mutations can be found in Figure 1. Table S3: Response rates and kinetics with VEN-based regimens and HSCT bridging data in relapsed/refractory and MRD-positive patients sub-cohorts. CCR, composite complete remission; CR, complete remission; CRi, complete remission with incomplete counts recovery; FLT3i, FLT3 inhibitor; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation; ITT, intention-to-transplant; MRD, minimal residual disease. Table S4: Survival data according to relevant clinical and molecular covariates. EFS, event-free survival. HSCT, hematopoietic stem cell transplantation. HR, hazard ratio. OS, overall survival. Table S5: Nonhematological adverse events (whole cohort). Grading according to common terminology criteria for adverse events (CTCAE) version 5.0. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia Harinder Gill, Francesca Palandri, David M. Ross, Joachim R. Göthert, Tara Cochrane, Stephen R. Larsen, Anna B. Halpern, Jake Shortt, James M. Rossetti, James Liang, Monia Marchetti, Andrew J. Wilson, Andrew J. Innes, Merit Hanna, Nicola Vianelli, William S. Stevenson, Alessandro M. Vannucchi, Maria Kleppe, Jessica Flynn, Georges Natsoulis, Claire N. Harrison, Hugh Young Rienhoff Blood Advances, 2026 Novel treatments that can improve outcomes of essential thrombocythemia (ET) are needed. In a phase 2 trial, participants with ET who required cytoreduction and had inadequate response to, or were intolerant of, ≥1 standard therapy received bomedemstat at a starting dose of 0.6 mg/kg per day, titrated to achieve a target platelet count (200 × 109/L to 400 × 109/L). Primary end points were safety and response, defined as a platelet count of ≤400 × 109/L without new thromboembolic events. Of 73 who received bomedemstat, at 24 weeks, 49 of 64 evaluable participants (77%) achieved a response. Durable reductions in platelet count (≤400 × 109/L for ≥12 weeks) were observed in 52 of 72 participants (72%). Durable reduction in white blood cell count (<10 × 109/L for ≥12 weeks) was observed in 61 of 72 participants (85%); of 10 participants with elevated white blood cell count at baseline, 9 had normal white blood cell count (<10 × 109/L) at week 24. Hemoglobin levels remained stable. After 24 weeks of treatment, a decrease in variant allele frequency of CALR, JAK2, or MPL was observed in 39 of 46 (85%) evaluable participants. By week 24, 2 of 73 participants (3%) had experienced ≥1 thrombotic event, and 15 of 73 (21%) experienced ≥1 hemorrhagic event. During overall treatment period, grade 3 or 4 adverse events (AEs) occurred in 34 of 73 participants (47%). AEs led to temporary treatment interruption in 29 participants (40%) and permanent discontinuation in 11 (15%). No participants died due to AEs. Bomedemstat had clinically relevant activity and manageable safety in participants with ET. This trial was registered at www.clinicaltrials.gov as #NCT04254978.
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study Jason Gotlib, Andreas Reiter, Deepti H. Radia, Iván Álvarez-Twose, Michael W. Deininger, Tracy I. George, Jens Panse, Andrzej Mital, Kristen M. Pettit, Alessandro M. Vannucchi, Uwe Platzbecker, Olivier Hermine, Amro Elshoury, Cristina Bulai Livideanu, Ruben Mesa, Celalettin Ustun, Massimo Triggiani, Ingunn Dybedal, Joseph G. Jurcic, Roberta Zanotti, Stephen T. Oh, Abdulraheem Yacoub, Elizabeth O. Hexner, Prithviraj Bose, Stephanie G. Lee, Wolfgang R. Sperr, Elizabeth A. Griffiths, Matthew Butler, Johannes Lübke, Ilda Bidollari, Hui-Min Lin, Svetlana Rylova, Saša Dimitrijević, Javier I. Muñoz-González, Daniel J. DeAngelo Blood Advances, 2026 Advanced systemic mastocytosis (AdvSM), a clonal hematologic neoplasm driven predominantly by D816V-mutant KIT, is often characterized by organ damage. Associated hematologic neoplasms (AHNs; usually myeloid) are often present, leading to poor survival. We report on the oral, highly selective, potent KIT D816V inhibitor avapritinib (200 mg once daily, starting dose) with >4 years follow-up from the fully enrolled PATHFINDER study. End points included overall response rate (ORR; primary), duration of response (DOR), progression-free survival (PFS), overall survival (OS), changes in objective biomarkers of disease, and safety (all secondary). Of 107 patients with AdvSM (including 71 [66%] with SM-AHN; overall population median follow-up, 49 months), 83 were response-evaluable. ORR was 73% (95% confidence interval, 63-83). Median DOR was 58 months; PFS, 51 months, and OS, 62 months. Disease progression occurred in 21 of 107 patients (20%), predominantly in SM-AHN and largely driven by the AHN. Reductions in objective biomarkers of disease were observed. Most frequent (≥30% patients) treatment-emergent adverse events (TEAEs; any grade; grade ≥3) were thrombocytopenia (58%; 31%); periorbital edema (57%; 6%), anemia (54%; 33%), peripheral edema (48%; 2%), and diarrhea (36%; 5%). Adverse events of special interest were cognitive effects (34%; 8%) and intracranial bleeds (4%; 2%). Eleven (10%) patients experienced TEAEs leading to death, of which 1 was deemed related to avapritinib by the principal investigator. With 4-year follow-up, patients with AdvSM treated with avapritinib experienced deep and durable responses and a favorable benefit-risk profile. This trial was registered at www.ClinicalTrials.gov as #NCT03580655.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib Alessandro M. Vannucchi, Jay L Patel, Jean-Jacques Kiladjian Blood, 2026 Myeloid/Lymphoid neoplasms with FGFR1 rearrangement (M/LN-FGFR1) are rare, heterogenous diseases due to fusion transcripts originated by translocations of FGFR1 with different partners, resulting in constitutive FGFR1-mediated signaling. Presentation varies from chronic myeloid neoplasms to acute leukemia or lymphoma and extramedullary localizations are common. Outside allogeneic stem cell transplantation (ASCT), survival with conventional therapy is dismal, representing an unmet clinical need. We summarize here the data that led to approval of pemigatinib, a FGFR1 inhibitor, showing unprecedented efficacy in M/LN-FGFR1.
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, James M. Dolezal, Andrew T. Kuykendall, Raffaella Santi, Ling Zhang, Avani M. Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Mohamed E. Salama, Alexander T. Pearson, Ronald Hoffman Leukemia, 2026 Prefibrotic primary myelofibrosis (prePMF) and essential thrombocythemia (ET) are distinct myeloproliferative neoplasms (MPNs) with overlapping clinical features, often leading to diagnostic uncertainty. We developed an artificial intelligence (AI) framework with human interpretability to distinguish prePMF from ET using digitized hematoxylin and eosin-stained bone marrow biopsy (BMB) slides. Trained on an initial cohort of MPN patients with thrombocytosis, the AI model achieved an AUROC of 0.89 and accuracy of 92.3%. To assess the image features guiding predictions, we generated synthetic images which potentially exaggerate disease-specific morphologies. In a blinded survey, hematopathologists reviewed both real and AI-generated images. While human experts frequently agreed with AI predictions on diagnosis with real images, diagnostic discordance reached up to 88% for AI-generated ET images despite being correctly predicted by AI. We further quantified marrow cellularity and adiposity in the real and generated images, which revealed a higher proportion of fat content in all ET images (42.0%) compared to prePMF (28.9%). These findings suggest that AI can utilize morphological cues distinct from current established diagnostic criteria, such as proportion of adiposity to distinguish types of MPNs. Thus, an AI-assisted diagnostic tool underscores the potential of AI to augment histopathologic evaluation and allow identification of more specific subpopulations of forms of MPNs.
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis Barbara Mora, Matteo Franchi, Ludovica Margotto, Olivia Leoni, Daniela D'ippoliti, Emanuela Carloni, Ilaria Cozzi, Enrica Santelli, Fabrizio Gemmi, Claudia Szasz, Margherita Maffioli, Carmelo Gurnari, Enrico Attardi, Daniele Cattaneo, Marta Bortolotti, Nicola Stefano Fracchiolla, Alessandra Iurlo, Giovanni Corrao, Matteo Giovanni Della Porta, Alessandro Maria Vannucchi, Maria Teresa Voso, Paola Guglielmelli, Francesco Passamonti Hemasphere, 2026
JAK inhibitor selection in challenging scenarios of myelofibrosis: A review Pankit Vachhani, Ruben Mesa, John Mascarenhas, Raajit Rampal, Stephen T. Oh, Alessandro Maria Vannucchi, Maria Laura Fox, Francesca Palandri, Francesco Passamonti, Jean-Jacques Kiladjian, Mahshid Azimi, Claire Harrison, Prithviraj Bose Haematologica, 2026
Downregulation of CD19 Expression Associates With Mantle Cell Lymphoma Relapse Following CAR-T Cell Therapy Benedetta Peruzzi, Alessio Mazzoni, Ilaria Cutini, Francesca Matani, Roberto Caporale, Sara Bencini, Sara Pratesi, Laura Maggi, Manuela Capone, Anna Vanni, Giulia Lamacchia, Lucia Bartoli, Francesco Liotta, Lorenzo Cosmi, Benedetta Puccini, Luca Nassi, Benedetta Sordi, Chiara Camerini, Alessandro Maria Vannucchi, Chiara Nozzoli, Francesco Annunziato European Journal of Immunology, 2026
Safety of Prophylactic Anakinra in Patients Treated with CD28-Based CD19 Chimeric Antigen Receptor-T Cells for R/R B-Cell Lymphoma Ilaria Cutini, Chiara Camerini, Giacomo Coltro, Antonella Gozzini, Edoardo Simonetti, Mirella Giordano, Gaia Mirabella, Alessio Mazzoni, Francesca Matani, Roberto Caporale, Sara Bencini, Benedetta Peruzzi, Luca Nassi, Benedetta Puccini, Benedetta Sordi, Andrea Pasquini, Corrado Imbriani, Francesco Annunziato, Alessandro Maria Vannucchi, Chiara Nozzoli Transplantation and Cellular Therapy, 2026
Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis Barbara Mora, Francesca Palandri, Paola Guglielmelli, Andrew T. Kuykendall, Margherita Maffioli, Alessandra Iurlo, Valerio De Stefano, Silvia Salmoiraghi, Timothy Devos, Federico Itri, Francisco Cervantes, Jean-Jacques Kiladjian, Matteo G. Della Porta, Francesco Albano, Jason Gotlib, Giulia Benevolo, Marianna Caramella, Marco Ruggeri, Elisa Rumi, David M. Ross, Chiara Pessina, Ilaria Colugnat, Francesco Orsini, Giorgia Micucci, Giada Rotunno, Rami S. Komrokji, Daniele Cattaneo, Patrizia Chiusolo, Marta Bortolotti, Tiziano Barbui, Daniela Cilloni, Massimo Breccia, Giuseppe A Palumbo, Filippo Branzanti, Ludovica Margotto, Matteo Franchi, Alessandro M. Vannucchi, Francesco Passamonti Blood, 2026
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40 William J. Tapper, Ahmed A. Z. Dawoud, Joannah Score, Andrew J. Chase, E. Joanna Baxter, Joanne Ewing, Louise Wallis, Paola Guglielmelli, Dolors Colomer, Beatriz Bellosillo, Montse Gomez, Juan Carlos Hernández-Boluda, Carlos Besses, Francisco Cervantes, Steffen Koschmieder, Anthony R. Green, Andreas Reiter, Alessandro Vannucchi, Claire Harrison, Nicholas C. P. Cross Blood, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rűdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui Blood Cancer Journal, 2025
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML Francesco Mannelli, Matteo Piccini, Marco Frigeni, Giacomo Gianfaldoni, Sara Bencini, Silvia Salmoiraghi, Barbara Scappini, Benedetta Peruzzi, Roberto Caporale, Gaia Ciolli, Francesca Crupi, Laura Fasano, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Fiorenza Vanderwert, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Danilo Tarantino, Chiara Maccari, Francesco Annunziato, Orietta Spinelli, Paola Guglielmelli, Alessandro Rambaldi, Alessandro M. Vannucchi Blood Cancer Journal, 2025
Triple A Plus (AAA+) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients Ayalew Tefferi, Giuseppe G. Loscocco, Lior Rokach, Tamar Tadmor, Priyansh Faldu, Guy Melamed, Hilel Alapi, Maymona Abdelmagid, Rania M. Abdelaziz, Muhammad Yousuf, Merry Nakhleh, Animesh Pardanani, Kebede H. Begna, Mirnal M. Patnaik, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Kaaren K. Reichard, Rong He, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi American Journal of Hematology, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis David M. Ross, Florian H. Heidel, Andrew Charles Perkins, Andreas Reiter, Carl Crodel, Caroline Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Jagannath Kota, Anirudh Prahallad, Monika Wroclawska, Min Lu, Claire N. Harrison Blood Advances, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design Valerio De Stefano, Francesco Passamonti, Francesca Palandri, Francesco Ramundo, Elena Rossi, Silvia Betti, Lorenzo Fagiolo, Paola Guglielmelli, Davide Pio Abagnale, Novella Pugliese, Daniele Cattaneo, Alessandra Iurlo, Filippo Branzanti, Alessandra Dedola, Hillary Catellani, Alessia Tieghi, Marco Basso, Elisabetta Calistri, Elena Maria Elli, Elena Masselli, Erika Morsia, Giulia Benevolo, Massimo Breccia, Vincenza de Fazio, Maria Di Perna, Monia Marchetti, Marco Santoro, Agostino Tafuri, Chiara Castiglioni, Chiara Rotella, Sergio Siragusa, Alessandro Maria Vannucchi, and Annals of Hematology, 2025
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C.P. Cross, Joanna Drozd-Sokolowska, Vaneuza Araújo Moreira Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire N. Harrison, Gabriela S Hobbs, Tania Jain, Joseph D. Khoury, Jean-Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel Howard Wiseman, Ibrahim Yakoub-Agha, Donal P McLornan Blood, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron T. Gerds, Alessandro M. Vannucchi, Francesca Palandri, Sung-Eun Lee, Vikas Gupta, Alessandro Lucchesi, Stephen T. Oh, Andrew T. Kuykendall, Andrea Patriarca, Alberto Álvarez-Larrán, Ruben Mesa, Jean-Jacques Kiladjian, Moshe Talpaz, Joseph M. Scandura, David Lavie, Morgan Harris, Sarah-Katharina Kays, Qing Li, Rainer Boxhammer, Barbara Brown, Anna-Maria Jegg, Claire N. Harrison, John Mascarenhas Nature Medicine, 2025
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G. Loscocco, Saubia Fathima, Kebede H. Begna, Aref Al‐Kali, James Foran, Jeanne Palmer, Talha Badar, Mrinal M. Patnaik, Kaaren K. Reichard, Rong He, Cinthya J. Zepeda Mendoza, Mithun Shah, Attilio Orazi, Daniel A. Arber, Animesh Pardanani, Alessandro M. Vannucchi, Devendra Hiwase, Naseema Gangat, Paola Guglielmelli American Journal of Hematology, 2025
Polycythaemia vera Claire N. Harrison, Tiziano Barbui, Prithviraj Bose, Jean-Jacques Kiladjian, John Mascarenhas, Mary Frances McMullin, Ruben Mesa, Alessandro M. Vannucchi Nature Reviews Disease Primers, 2025
When and how to transplant in myelofibrosis–recent trends Naman Sharma, Giuseppe G. Loscocco, Naseema Gangat, Paola Guglielmelli, Animesh Pardanani, Alessandro M. Vannucchi, Hassan B. Alkhateeb, Ayalew Tefferi, Vincent T. Ho Leukemia and Lymphoma, 2025
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan Carlos Hernandez-Boluda, Prithviraj Bose, Konstanze Döhner, Martin Ellis, Naseema Gangat, Jacqueline S. Garcia, Heinz Gisslinger, Jason Gotlib, Paola Guglielmelli, Vikas Gupta, Claire N. Harrison, Elizabeth O. Hexner, Gabriela S Hobbs, Jean-Jacques Kiladjian, Steffen Koschmieder, Nicolaus Kröger, Andrew T Kuykendall, Giuseppe Gaetano Loscocco, John O. Mascarenhas, Lucia Masarova, Ruben Mesa, Barbara Mora, Olatoyosi Odenike, Stephen T. Oh, Animesh D Pardanani, Anand A Patel, Naveen Pemmaraju, Alessandro Rambaldi, Raajit K. Rampal, Shireen Sirhan, Natasha Szuber, Moshe Talpaz, Pankit Vachhani, Alessandro M. Vannucchi, Tiziano Barbui Blood, 2024
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts Lara Tavernari, Sebastiano Rontauroli, Ruggiero Norfo, Margherita Mirabile, Monica Maccaferri, Barbara Mora, Elena Genovese, Sandra Parenti, Chiara Carretta, Elisa Bianchi, Matteo Bertesi, Francesca Pedrazzi, Elena Tenedini, Silvia Martinelli, Maria Teresa Bochicchio, Paola Guglielmelli, Leonardo Potenza, Alessandro Lucchesi, Francesco Passamonti, Enrico Tagliafico, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini, and American Journal of Hematology, 2024
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms Chiara Carretta, Sandra Parenti, Matteo Bertesi, Sebastiano Rontauroli, Filippo Badii, Lara Tavernari, Elena Genovese, Marica Malerba, Elisa Papa, Samantha Sperduti, Elena Enzo, Margherita Mirabile, Francesca Pedrazzi, Anita Neroni, Camilla Tombari, Barbara Mora, Margherita Maffioli, Marco Mondini, Marco Brociner, Monica Maccaferri, Elena Tenedini, Silvia Martinelli, Niccolò Bartalucci, Elisa Bianchi, Livio Casarini, Leonardo Potenza, Mario Luppi, Enrico Tagliafico, Paola Guglielmelli, Manuela Simoni, Francesco Passamonti, Ruggiero Norfo, Alessandro Maria Vannucchi, Rossella Manfredini, and Leukemia, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis Aaron T. Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro M. Vannucchi, Rami Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam J. Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne M. Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti Blood Advances, 2024
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis Daniele Capitanio, Francesca R. Calledda, Vittorio Abbonante, Daniele Cattaneo, Manuela Moriggi, Bartalucci Niccolò, Cristina Bucelli, Delfina Tosi, Umberto Gianelli, Alessandro Maria Vannucchi, Alessandra Iurlo, Cecilia Gelfi, Alessandra Balduini, Alessandro Malara Leukemia, 2024
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Ilaria Colugnat, Raffaela Aquila, Manjola Balliu, Chiara Maccari, Simone Romagnoli, Chiara Paoli, Elena Nacca, Lorenzo Fagiolo, Margherita Maffioli, Tiziano Barbui, Francesco Passamonti, Alessandro M. Vannucchi American Journal of Hematology, 2024
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial Bianca Rocca, Alberto Tosetto, Giovanna Petrucci, Elena Rossi, Silvia Betti, Denise Soldati, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Rossella Renso, Maria Luigia Randi, Irene Bertozzi, Giuseppe Gaetano Loscocco, Alessandra Ricco, Giorgina Specchia, Alessandro M. Vannucchi, Francesco Rodeghiero, Valerio De Stefano, Carlo Patrono, and American Journal of Hematology, 2024
CALR mutation burden in essential thrombocythemia and disease outcome Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi Blood, 2024
Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion Caterina Tretti Parenzan, Anna Dal Molin, Giorgia Longo, Enrico Gaffo, Alessia Buratin, Alice Cani, Elena Boldrin, Valentina Serafin, Paola Guglielmelli, Alessandro M. Vannucchi, Giovanni Cazzaniga, Andrea Biondi, Franco Locatelli, Lueder H. Meyer, Barbara Buldini, Geertruij te Kronnie, Silvia Bresolin, Stefania Bortoluzzi Blood Advances, 2024
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Christian Recher, Jean-Jacques Kiladjian, Stephen T. Oh, Aaron T. Gerds, Timothy Devos, Francesco Passamonti, Alessandro M. Vannucchi, Miklos Egyed, Ewa Lech-Maranda, Andrzej Pluta, Lars Nilsson, Kazuya Shimoda, Donal McLornan, Jun Kawashima, Barbara Klencke, Mei Huang, Bryan Strouse, Claire Harrison Haematologica, 2024
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes Tiziano Barbui, Alessandra Carobbio, Valerio De Stefano, Alberto Alvarez-Larran, Arianna Ghirardi, Greta Carioli, Francesca Fenili, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Laura Calabresi, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Francesca Gesullo, Silvia Betti, Francesco Ramundo, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Daniele Cattaneo, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi, Alessandro Maria Vannucchi Annals of Hematology, 2024
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Giada Rotunno, Eva Angori, Filippo C. Borri, Ayalew Tefferi, Alessandro M. Vannucchi Blood Cancer Journal, 2023
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients Tiziano Barbui, Alessandra Carobbio, Juergen Thiele, Naseema Gangat, Elisa Rumi, Alessandro Rambaldi, Alessandro M. Vannucchi, Ayalew Tefferi, Georg Jeryczynski, Leonhard Müllauer, Rakhee Vaidya, Nanna H. Sulai, Animesh Pardanani, Dirk R. Larson, Mario Cazzola, Ilaria Casetti, Guido Finazzi, Lisa Pieri, Heinz Gisslinger, Bettina Gisslinger, Francesco Rodeghiero, Marco Ruggeri, Maria Luigia Randi, Irene Bertozzi, Francesco Passamonti, and Blood Cancer Journal, 2023
MANIFEST: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Marielle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek, Natalia Curto-García, Claire Harrison, Vikas Gupta Journal of Clinical Oncology, 2023
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms Laura Calabresi, Chiara Carretta, Simone Romagnoli, Giada Rotunno, Sandra Parenti, Matteo Bertesi, Niccolò Bartalucci, Sebastiano Rontauroli, Chiara Chiereghin, Sara Castellano, Giulia Gentili, Chiara Maccari, Fiorenza Vanderwert, Francesco Mannelli, Matteo Della Porta, Rossella Manfredini, Alessandro Maria Vannucchi, Paola Guglielmelli American Journal of Hematology, 2023
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis John Mascarenhas, Anna Rita Migliaccio, Heidi Kosiorek, Rupali Bhave, Jeanne Palmer, Andrew Kuykendall, Ruben Mesa, Raajit K. Rampal, Aaron T. Gerds, Abdulraheem Yacoub, Kristen Pettit, Moshe Talpaz, Rami Komrokji, Marina Kremyanskaya, Agapito Gonzalez, Frank Fabris, Kathryn Johnson, Mikaela Dougherty, Erin McGovern, Juan Arango Ossa, Dylan Domenico, Noushin Farnoud, Rona Singer Weinberg, Amy Kong, Vesna Najfeld, Alessandro Maria Vannucchi, Francesca Arciprete, Maria Zingariello, Mario Falchi, Mohamed E. Salama, Carolyn Mead-Harvey, Amylou Dueck, Lilian Varricchio, Ronald Hoffman Clinical Cancer Research, 2023
Diagnostic and therapeutic challenges in mast cell sarcoma Francesco Mannelli, Francesca Gesullo, Carmela Mannarelli, Fiorenza Vanderwert, Stefano Lazzi, Francesco Mungai, Valentina Berti, Raffaella Santi, Paola Guglielmelli, Alessandro M. Vannucchi American Journal of Hematology, 2023
Biological drivers of clinical phenotype in myelofibrosis John Mascarenhas, Hélène F. E. Gleitz, Helen T. Chifotides, Claire N. Harrison, Srdan Verstovsek, Alessandro Maria Vannucchi, Raajit K. Rampal, Jean-Jacques Kiladjian, William Vainchenker, Ronald Hoffman, Rebekka K. Schneider, Alan F. List Leukemia, 2023
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis Benedetta Sordi, Fiorenza Vanderwert, Francesca Crupi, Francesca Gesullo, Roberta Zanotti, Patrizia Bonadonna, Lara Crosera, Chiara Elena, Nicolas Fiorelli, Jacqueline Ferrari, Federica Grifoni, Mariarita Sciumè, Roberta Parente, Massimo Triggiani, Boaz Palterer, Valentina Mecheri, Fabio Almerigogna, Raffaella Santi, Lisa Di Medio, Maria Luisa Brandi, Maria Loredana Iorno, Isabella Ciardetti, Sara Bencini, Francesco Annunziato, Carmela Mannarelli, Lisa Pieri, Paola Guglielmelli, Francesco Mannelli, Alessandro M. Vannucchi Journal of Allergy and Clinical Immunology, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N Harrison, Barbara J Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa, Adi Shacham Abulafia, Haifa Kathrin Al-Ali, Bjorn Andreasson, Anna Angona, Rosa Ayala, Soo-Mee Bang, Bruce Bank, Fiorenza Barraco, Eloise Beggiato, Fleur Samantha Benghiat, MassimiliaNo Bonifacio, Claire Bories, Gabriela Borsaru, Mette Brabrand, Andrei Braester, Andes Broliden, Veronika Buxhofer-Ausch, Nathalie Cambier, Marianna Caramella, Benjamin Carpentier, Nicola Cascavilla, Maria Giraldo Castellano, Hung Chang, Chih-Cheng Chen, June-Won Cheong, Yunsuk Choi, Philip Choi, Maria Teresa Corsetti, Isabel Montero Cuadrado, Julia Cunningham, Gandhi Laurent Damaj, Valerio De Stefano, Robert Delage, Regina Garcĺa Delgado, Jose Miguel Torregrosa Diaz, Péter Dombi, Viviane Dubruille, Miklós Egyed, Daniel El Fassi, Anna Elinder-Camburn, Elena Maria Elli, Martin Ellis, Carmen Fava, Salman Fazal, Angela Fleischman, Lynda Foltz, Laura Fox, Nashat Gabrail, Jose Valentĺn Garcĺa-Gutiérrez, Aaron Gerds, Stephane Girault, Heinz Gisslinger, Alexandru Gluvacov, Yeow Tee Goh, Joachim Göthert, Nikki Granacher, Sebastian Grosicki, Vikas Gupta, Evgeni (Evgueniy) Hadjiev (Hadzhiev), Kaoutar Hafraoui, Aryan Hamed, Claire Harrison, Hans Hasselbalch, Hanns Hauser, Mark Heaney, Holger Hebart, Jesus Maria Hernandez Rivas, Victor Higuero Saavedra, Christopher Hillis, Hsin-An Hou, Jonathan How, Daniel Huang, Marek Hus, Arpad Illés, Alessandro Isidori, Alessandra Iurlo, Vadim Ivanov, Peter Johansson, Chul Won Jung, Jean-Jacques Kiladjian, Ilya Kirgner, Maya Koren-Michowitz, Steffen Koschmieder, Szabolcs Ors Kosztolanyi, Natalia Kreiniz, Andrew Kuykendall, Jonathan Lambert, Kamel Laribi, Axelle Lascaux, Noa Lavie, David Lavie, Mihaela Lazaroiu, Michael Leahy, Ewa Lech-Maranda, Sung-Eun Lee, Won Sik Lee, Ollivier Legrand, Roberto Lemoli, James Liang, Sung-Nam Lim, Michael Loschi, Alessandro Lucchesi, Ioan Macarie, Jean-Pierre Marolleau, Maurizio Martelli, Jiri Mayer, James McCloskey, Christopher McDermott, Donal McLornan, Brandon McMahon, Priyanka Mehta, Ruben Mesa, Gábor Mikala, Dragana Milojkovic, Philippe Mineur, Elena Mishchenko, Joon Ho Moon, Zsolt Nagy, Srinivasan Narayanan, Casey O'Connell, Luminita Ocroteala, Stephen Oh, Mario Ojeda-Uribe, Kiat Hoe Ong, Folashade Otegbeye, Jeanne Palmer, Fabrizio Pane, Francesco Passamonti, Andrea Patriarca, Andrew Perkins, Giuseppe Pietrantuono, Mark Plander, Uwe Platzbecker, Ritam Prasad, Witold Prejzner, Tobias Rachow, Atanas Radinoff, László Rejtő, Ciro Rinaldi, Tadeusz Robak, Maria Angeles Fernandez Rodriguez, Aaron Ronson, David Ross, Tomasz Sacha, Parvis Sadjadian, Antonio Salar, Guillermo Sanz Santillana, Christof Scheid, Aline Schmidt, Marianne Tang Severinsen, Vera Stoeva, Paweł Szwedyk, Mario Tiribelli, Karolin Trautmann-Grill, Amy Trottier, Nikolay Tzvetkov, Janusz van Droogenbroeck, Alessandro Vannucchi, Srdan Verstovsek, Nicola Vianelli, Nikolas von Bubnoff, Dominik Wolf, Dariusz Woszczyk, Tomasz Woźny, Tomasz Wróbel, Blanca Xicoy, Su-Peng Yeh, Sung-Soo Yoon Lancet, 2023
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19 Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade‐Campos, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria‐Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez‐Larran, Jean‐Jacques Kiladjian, Estefanía Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia‐Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Giuseppe Carli, Juan Carlos Hernandez‐Boluda, Santiago Osorio, Gonzalo Carreno‐Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Marta Bellini, Natalia Curto‐Garcia, Alessandro Rambaldi, Alessandro Maria Vannucchi American Journal of Hematology, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia Eric J Duncavage, Adam Bagg, Robert P. Hasserjian, Courtney D. DiNardo, Lucy A. Godley, Ilaria Iacobucci, Siddhartha Jaiswal, Luca Malcovati, Alessandro M. Vannucchi, Keyur P Patel, Daniel A. Arber, Maria E Arcila, Rafael Bejar, Nancy Berliner, Michael J. Borowitz, Susan Branford, Anna L Brown, Catherine A Cargo, Hartmut Döhner, Brunangelo Falini, Guillermo Garcia-Manero, Torsten Haferlach, Eva Hellström-Lindberg, Annette S. Kim, Jeffery M Klco, Rami S. Komrokji, Mignon L. Loh, Sanam Loghavi, Charles G. Mullighan, Seishi Ogawa, Ayalew Tefferi, Elli Papaemmanuil, Andreas Reiter, David Morrall Ross, Michael R Savona, Akiko Shimamura, Radek C. Skoda, Francesc Sole, Richard M. Stone, Attilio Orazi, Matthew J Walter, David Wu, Benjamin L. Ebert, Mario Cazzola Blood, 2022
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis Andreas Reiter, Juliana Schwaab, Daniel J. DeAngelo, Jason Gotlib, Michael W. Deininger, Kristen M. Pettit, Iván Alvarez-Twose, Alessandro M. Vannucchi, Jens Panse, Uwe Platzbecker, Olivier Hermine, Ingunn Dybedal, Hui-Min Lin, Svetlana N. Rylova, Katrin Ehlert, Saša Dimitrijević, Deepti H. Radia Blood Advances, 2022
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Greta Carioli, Alessandro Rambaldi, Maria Chiara Finazzi, Marta Bellini, Elisa Rumi, Daniele Vanni, Oscar Borsani, Francesco Passamonti, Barbara Mora, Marco Brociner, Paola Guglielmelli, Chiara Paoli, Alberto Alvarez-Larran, Ana Triguero, Marta Garrote, Helna Pettersson, Björn Andréasson, Giovanni Barosi, Alessandro Maria Vannucchi Blood Cancer Journal, 2022
Breakthrough infections in MPN-COVID vaccinated patients Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreno-Tarragona, Andrea Patriarca, Haifa Kathrin Al-Ali, Maria Marcio Miguel Andrade-Campos, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro Mazo, Jean-Jacques Kiladjian, Estefanía Bolaños Calderón, Florian H. Heidel, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagues Serrano, Rajko Kusec, Blanca Xicoy Cirici, Margarita Guenova, Begona Navas Elorza, Anna Angona, Edyta Cichocka, Anna Kulikowska de Nałęcz, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro Maria Vannucchi Blood Cancer Journal, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, Elisa Rumi, Margherita Maffioli, Francesca Palandri, Valerio De Stefano, Marianna Caramella, Silvia Salmoiraghi, Jean-Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Marco Ruggeri, Richard T. Silver, Francesco Albano, Giulia Benevolo, David M. Ross, Matteo G. Della Porta, Timothy Devos, Giada Rotunno, Rami S. Komrokji, Ilaria C. Casetti, Michele Merli, Marco Brociner, Domenica Caramazza, Giuseppe Auteri, Tiziano Barbui, Daniele Cattaneo, Lorenza Bertù, Luca Arcaini, Alessandro M. Vannucchi, Francesco Passamonti Leukemia, 2022
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi Blood, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Andrew T Kuykendall, Alessandro M Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Alvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John Mascarenhas Future Oncology, 2022
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5 Marc E. Rothenberg, Florence Roufosse, Stanislas Faguer, Gerald J. Gleich, Jonathan Steinfeld, Steven W. Yancey, Eleni Mavropoulou, Namhee Kwon, Gabriel Ricardo García, Adriana Sosso, Luis Wehbe, Anahí Yañez, Daniël Blockmans, Florence Roufosse, Martti Anton Antila, Daniela Blanco, Sergio Grava, Marina Andrade Lima, Andreia Luisa Francisco Pez, Stanislas Faguer, Mohamed A. Hamidou, Jean-Emmanuel Kahn, Guillaume Lefévre, Knut Brockow, Peter M. Kern, Andreas J. Reiter, Bastian Walz, Tobias Welte, Fabrizio Pane, Alessandro M. Vannucchi, Ruth Cerino-Javier, Alfredo Gazca-Aguilar, Dante D. Hernández-Colín, Héctor Glenn Valdéz-López, Izabela R. Kupryś-Lipińska, Jacek Musial, Witold Prejzner, Eniko Mihaly, Viola Popov, Mihnea Tudor Zdrenghea, Sergey V. Gritsaev, Vladimir Ivanov, Nikolay Tsyba, Aránzazu Alonso, Maria Cinta Cid Xutgla, Maria Laura Fox, Regina Garcia Delgado, Jesús María Hernández Rivas, Guillermo Sanz Santillana, Ana Isabel González, Andrew J. Wardlaw, Praveen Akuthota, Joseph H. Butterfield, Geoffrey L. Chupp, John B. Cox, Gerald J. Gleich, Devi Jhaveri, Marc E. Rothenberg Journal of Allergy and Clinical Immunology in Practice, 2022
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies Austin G. Kulasekararaj, Morag Griffin, Saskia Langemeijer, Kensuke Usuki, Alexander Kulagin, Masayo Ogawa, Ji Yu, Arshad Mujeebuddin, Jun‐ichi Nishimura, Jong Wook Lee, Régis Peffault de Latour, Aigul Latypova, Wilma Barcellini, Fiorenza Barraco, Donald Beam, Peter Bettelheim, Elena Borisenkova, Andres Brodsky, Benedict Carnley, Jaroslav Cermak, Tsai‐Yun Chen, Lee Ping Chew, Teng Keat Chew, Chul Won Choi, Yunsuk Choi, Joo Seop Chung, Sophie De Guibert, Timothy Devos, Yuri Dunaev, Jadwiga Dwilewicz‐Trojaczek, Yoko Edahiro, Iliya Elykomov, Maria Ines Engelberger, Fabrizio Pomponi, Wolfgang Fuereder, Nobuharu Fujii, Shinichiro Fujiwara, Piero Galieni, Anna Gaya Valls, Stéphane Girault, David Gomez Almaguer, F. Ataulfo Gonzalez Fernandez, Sergey Gritsaev, Eren Gunduz, Chattree Hantaweepant, Hiroshi Harada, Martin Höglund, Wei‐Han Huang, Azlan Husin, Takayuki Ikezoe, Ken Ishiyama, Yoshikazu Ito, Jun Ho Jang, Deog‐Yeon Jo, Ka‐Won Kang, James Kennedy, Hyo Jung Kim, Jeong‐A Kim, Jin Seok Kim, Fumihiko Kimura, Masayoshi Kobune, Hiroshi Kosugi, Alexander Kulagin, Austin Kulasekararaj, Kuan‐Ming Lai, Loree Larratt, Gyeong‐Won Lee, Jae Hoon Lee, Je‐Hwan Lee, Jong Wook Lee, Chien‐Chin Lin, Elena Lukina, Elena Martynova, Itaru Matsumura, Galina Meike, Sandra Fátima Menosi Gualandro, Natalia Minaeva, Yasuo Mori, Kimio Morita, Fernanda Maria Morselli Ramalho, Yeung‐Chul Mun, Petra Muus, Alexander Myasnikov, Kensuke Naito, Haruhiko Ninomiya, Ayako Nogami, Rosario Notaro, Emilio Ojeda Gutierrez, Masaya Okada, Shinichiro Okamoto, Tatiana Olkhovik, Fabrizio Pane, Ronald Paquette, Joon Seong Park, Régis Peffault de la Tour, Caroline Piatek, Agnieszka Piekarska, Marcos Laercio Pontes Reis, Tatiana Pospelova, Vadim Ptushkin, Alexander Roeth, Ponlapat Rojnuckarin, Viviani de Lourdes Rosa Pessoa, Blanca Rossi, Sinari Salleh, Marco Aurelio Salvino de Araujo, Desmond Samuel, Natalya Saraeva, Hubert Schrezenmeier, Yury Shatokhin, Tatiana Shelekhova, Sang Kyun Sohn, Katerina Steinerova, Kazutaka Sunami, Sharifah Shahnaz Syed Abdul Kadir, Shinobu Tamura, Koen Theunissen, See Guan Toh, Akihiro Tomita, José Miguel Torregrosa Diaz, Yasutaka Ueda, Kensuke Usuki, Alessandro Maria Vannucchi, Pongtep Viboonjuntra, Iige Viigimaa, Svetlana Volkova, Ming‐Chung Wang, Jong‐Ho Won, Lily Lee Lee Wong, Voon Fei Wong, Eng Soo Yap, Su‐Peng Yeh, Ho‐Young Yhim, Yuji Yonemura, Sung‐Soo Yoon, Andrey Zhuravkov, and European Journal of Haematology, 2022
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis Claire Harrison, Florian H. Heidel, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Amjad Hayat, Francesco Passamonti, Eibhlin Conneally, Thomas Kindler, Bruno Martino, Daniel B. Lipka, Tommaso Stefanelli, Pantelia Roussou, Davide Germano, Jacqueline Ewan, Vincent Ribrag Hemasphere, 2022
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study Francesca Gorini, Michele Santoro, Anna Pierini, Lorena Mezzasalma, Silvia Baldacci, Elena Bargagli, Alessandra Boncristiano, Maurizia Rossana Brunetto, Paolo Cameli, Francesco Cappelli, Giancarlo Castaman, Barbara Coco, Maria Alice Donati, Renzo Guerrini, Silvia Linari, Vittoria Murro, Iacopo Olivotto, Paola Parronchi, Francesca Pochiero, Oliviero Rossi, Barbara Scappini, Andrea Sodi, Alessandro Maria Vannucchi, Alessio Coi Frontiers in Pharmacology, 2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing, Casey L. O'Connell, Jean-Jacques Kiladjian, Adam J. Mead, Elliott F. Winton, David S. Leibowitz, Valerio De Stefano, Murat O. Arcasoy, Craig M. Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T. Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Max F. Levine, Juan E. Arango Ossa, Erin McGovern, Lonette Sandy, Mohamad E. Salama, Vesna Najfeld, Joseph Tripodi, Noushin Farnoud, Alexander V. Penson, Rona Singer Weinberg, Leah Price, Judith D. Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K. Rampal, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman Blood, 2022
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia Alberto Tosetto, Bianca Rocca, Giovanna Petrucci, Silvia Betti, Denise Soldati, Elena Rossi, Andrea Timillero, Viviana Cavalca, Benedetta Porro, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Stefania Priolo, Maria Luigia Randi, Irene Bertozzi, Giuseppe Gaetano Loscocco, Alessandra Ricco, Giorgina Specchia, Alessandro Maria Vannucchi, Francesco Rodeghiero, Valerio De Stefano, Carlo Patrono, for the Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators Clinical Pharmacology and Therapeutics, 2022
Second versus first wave of COVID-19 in patients with MPN Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade-Campos, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian, Estefanía Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griessammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Marco Ruggeri, Juan Carlos Hernandez-Boluda, Santiago Osorio, Gonzalo Carreno-Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Masternak Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Lina Benajiba, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, Alessandro Maria Vannucchi Leukemia, 2022
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron Gerds, Vikas Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub Blood Advances, 2022
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study Paola Guglielmelli, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Chiara Maccari, Barbara Mora, Elisa Rumi, Ana Triguero, Maria Chiara Finazzi, Helna Pettersson, Chiara Paoli, Francesco Mannelli, Daniele Vanni, Alessandro Rambaldi, Francesco Passamonti, Alberto Alvarez-Larràn, Bjorn Andreasson, Alessandro M. Vannucchi, Tiziano Barbui Blood Advances, 2022
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis Elena Genovese, Margherita Mirabile, Sebastiano Rontauroli, Stefano Sartini, Sebastian Fantini, Lara Tavernari, Monica Maccaferri, Paola Guglielmelli, Elisa Bianchi, Sandra Parenti, Chiara Carretta, Selene Mallia, Sara Castellano, Corrado Colasante, Manjola Balliu, Niccolò Bartalucci, Raffaele Palmieri, Tiziana Ottone, Barbara Mora, Leonardo Potenza, Francesco Passamonti, Maria Teresa Voso, Mario Luppi, Alessandro Maria Vannucchi, Enrico Tagliafico, Rossella Manfredini, and Antioxidants, 2022
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial Jason Gotlib, Andreas Reiter, Deepti H. Radia, Michael W. Deininger, Tracy I. George, Jens Panse, Alessandro M. Vannucchi, Uwe Platzbecker, Iván Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lisa K. Hicks, Lambert Span, Ruben Mesa, Prithviraj Bose, Kristen M. Pettit, Mark L. Heaney, Stephen T. Oh, Jayita Sen, Hui-Min Lin, Brenton G. Mar, Daniel J. DeAngelo Nature Medicine, 2021
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study Gerald J. Gleich, Florence Roufosse, Geoffrey Chupp, Stanislas Faguer, Bastian Walz, Andreas Reiter, Steven W. Yancey, Jane H. Bentley, Jonathan Steinfeld, Gabriel Ricardo García, Pablo Pascale, Luis Wehbe, Daniël Blockmans, Florence Roufosse, Martti Anton Antila, Daniela Blanco, Andreia Luisa Francisco Pez, Stanislas Faguer, Jean-Emmanuel Kahn, Guillaume Lefévre, Antoine Neel, Peter M. Kern, Andreas J. Reiter, Bastian Walz, Tobias Welte, Fabrizio Pane, Alessandro M. Vannucchi, Ruth Cerino-Javier, Dante D. Hernández-Colín, Héctor Glenn Valdéz-López, Izabela R. Kupryś-Lipińska, Jacek Musial, Eniko Mihaly, Viola Maria Popov, Vladimir Ivanov, Nikolay Tsyba, Maria C. Cid, Maria Laura Fox, Guillermo Sanz Santillana, Andrew J. Wardlaw, Praveen Akuthota, Joseph H. Butterfield, Geoffrey L. Chupp, Gerald J. Gleich, Devi Jhaveri, Marc E. Rothenberg Journal of Allergy and Clinical Immunology in Practice, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies Francesco Passamonti, Alessandra Romano, Marco Salvini, Francesco Merli, Matteo G. Della Porta, Riccardo Bruna, Elisa Coviello, Ilaria Romano, Roberto Cairoli, Roberto Lemoli, Francesca Farina, Adriano Venditti, Alessandro Busca, Marco Ladetto, Massimo Massaia, Antonio Pinto, Luca Arcaini, Agostino Tafuri, Francesco Marchesi, Nicola Fracchiolla, Monica Bocchia, Daniele Armiento, Anna Candoni, Mauro Krampera, Mario Luppi, Valeria Cardinali, Sara Galimberti, Chiara Cattaneo, Elettra Ortu La Barbera, Roberto Mina, Francesco Lanza, Giuseppe Visani, Pellegrino Musto, Luigi Petrucci, Francesco Zaja, Paolo A. Grossi, Lorenza Bertù, Livio Pagano, Paolo Corradini, Enrico Derenzini, Monia Marchetti, Anna M. Scattolin, Alessandro Corso, Patrizia Tosi, Filippo Gherlinzoni, Carlo Gambacorti Passerini, Michele Cavo, Carmen Fava, Mauro Turrini, Carlo Visco, Patrizia Zappasodi, Michele Merli, Barbara Mora, Alessandro M. Vannucchi, and British Journal of Haematology, 2021
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis Sebastian Fantini, Sebastiano Rontauroli, Stefano Sartini, Margherita Mirabile, Elisa Bianchi, Filippo Badii, Monica Maccaferri, Paola Guglielmelli, Tiziana Ottone, Raffaele Palmieri, Elena Genovese, Chiara Carretta, Sandra Parenti, Selene Mallia, Lara Tavernari, Costanza Salvadori, Francesca Gesullo, Chiara Maccari, Michela Zizza, Alexis Grande, Silvia Salmoiraghi, Barbara Mora, Leonardo Potenza, Vittorio Rosti, Francesco Passamonti, Alessandro Rambaldi, Maria Teresa Voso, Cristina Mecucci, Enrico Tagliafico, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini Cancers, 2021
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients Tiziano Barbui, Valerio De Stefano, Alessandra Carobbio, Alessandra Iurlo, Alberto Alvarez-Larran, Beatriz Cuevas, Francisca Ferrer Marín, Alessandro M. Vannucchi, Francesca Palandri, Claire Harrison, Hassan Sibai, Martin Griesshammer, Massimiliano Bonifacio, Elena M. Elli, Chiara Trotti, Steffen Koschmieder, Giuseppe Carli, Giulia Benevolo, Jean-Christophe Ianotto, Swati Goel, Anna Falanga, Silvia Betti, Daniele Cattaneo, Eduardo Arellano-Rodrigo, Lara Mannelli, Nicola Vianelli, Andrew Doyle, Vikas Gupta, Kai Wille, Douglas Tremblay, John Mascarenhas Leukemia, 2021
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis John Mascarenhas, Rami S. Komrokji, Francesca Palandri, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L. Scott, Maria R. Baer, Ronald Hoffman, Olatoyosi Odenike, Alessandro M. Vannucchi, Jacqueline Bussolari, Eugene Zhu, Esther Rose, Laurie Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Faye M. Feller, Aleksandra Rizo, Jean-Jacques Kiladjian Journal of Clinical Oncology, 2021
Jak inhibition with ruxolitinib in patients with covid‐19 and severe pneumonia: Multicenter clinical experience from a compassionate use program in italy Alessandro Maria Vannucchi, Andrea Mortara, Andrea D’Alessio, Mara Morelli, Alberto Tedeschi, Moreno Benedetto Festuccia, Antonella D’Arminio Monforte, Enrico Capochiani, Carmine Selleri, Federico Simonetti, Annalisa Saracino, Davide Rapezzi, Maria Rita Badagliacca, Katia Falasca, Alfredo Molteni, Roberto Palazzolo, Giuliano Schettino, Monica Bocchia, Mauro Turrini, Paolo A. Ascierto, Mike Zuurman, Carole Paley, Paola Coco, Giuseppe Saglio Journal of Clinical Medicine, 2021
Long-term follow-up of recovered MPN patients with COVID-19 Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Giuseppe Rossi, Claire Harrison, Alberto Alvarez-Larran, Elena Maria Elli, Jean-Jaques Kiladjian, Mercedes Gasior Kabat, Alberto Marin Sanchez, Francesca Palandri, Marcio Miguel Andrade-Campos, Alessandro Maria Vannucchi, Gonzalo Carreno-Tarragona, Petros Papadopoulos, Keina Quiroz Cervantes, Maria Angeles Foncillas, Maria Laura Fox, Miguel Sagues Serrano, Elisa Rumi, Santiago Osorio, Giulia Benevolo, Andrea Patriarca, Begona Navas Elorza, Valentin Garcia-Gutierrez, Elena Magro Mazo, Francesca Lunghi, Massimiliano Bonifacio, Valerio De Stefano, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Anna Angona, Blanca Xicoy Cirici, Marco Ruggeri, Steffen Koschmieder, Marta Anna Sobas, Beatriz Cuevas, Daniele Cattaneo, Rosa Daffini, Marta Bellini, Natalia Curto-Garcia, Marta Garrote, Fabrizio Cavalca, Lina Benajiba, Beatriz Bellosillo, Paola Guglielmelli, Oscar Borsani, Silvia Betti, Silvia Salmoiraghi, Alessandro Rambaldi Blood Cancer Journal, 2021
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series Ilaria Tanasi, Massimiliano Bonifacio, Miriam Pizzolato, Federica Irene Grifoni, Mariarita Sciumè, Chiara Elena, Pietro Benvenuti, Francesco Mannelli, Roberta Parente, Donatella Schena, Luigi Scaffidi, Patrizia Bonadonna, Cristina Papayannidis, Michela Rondoni, Marianna Criscuolo, Alessandro M. Vannucchi, Massimo Triggiani, Giovanni Martinelli, Mauro Krampera, Roberta Zanotti British Journal of Haematology, 2021
Mutations and thrombosis in essential thrombocythemia Paola Guglielmelli, Naseema Gangat, Giacomo Coltro, Terra L. Lasho, Giuseppe Gaetano Loscocco, Christy M. Finke, Erika Morsia, Benedetta Sordi, Natasha Szuber, Curtis A. Hanson, Animesh Pardanani, Alessandro M. Vannucchi, Ayalew Tefferi Blood Cancer Journal, 2021
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study Alessandro M. Vannucchi, Benedetta Sordi, Alessandro Morettini, Carlo Nozzoli, Loredana Poggesi, Filippo Pieralli, Alessandro Bartoloni, Alessandro Atanasio, Filippo Miselli, Chiara Paoli, Giuseppe G. Loscocco, Andrea Fanelli, Ombretta Para, Andrea Berni, Irene Tassinari, Lorenzo Zammarchi, Laura Maggi, Alessio Mazzoni, Valentina Scotti, Giorgia Falchetti, Danilo Malandrino, Fabio Luise, Giovanni Millotti, Sara Bencini, Manuela Capone, Marie Pierre Piccinni, Francesco Annunziato, Paola Guglielmelli, Francesco Mannelli, Giacomo Coltro, Duccio Fantoni, Miriam Borella, Enrica Ravenda, Benedetta Peruzzi, Roberto Caporale, Lorenzo Cosmi, Francesco Liotta, Letizia Lombardelli, Federica Logiodice, Anna Vanni, Lorenzo Salvati, Chiara Lazzeri, Manuela Bonizzoli, Adriano Peris, Giovanni Cianchi, Alberto Bosi, Michela Pucatti, Paolo Fontanari, Silvia Benemei, Marco Matucci Cerinic, Lucia Turco, and Leukemia, 2021
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide Onima Chowdhury, Jennifer O’Sullivan, Nikolaos Barkas, Guanlin Wang, Gemma Buck, Angela Hamblin, Ayalew Tefferi, Haifa K. Al-Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qian Jiang, Jean-Jacques Kiladjian, Ruben Mesa, Francesco Passamonti, Vincent Ribrag, Gary Schiller, Alessandro M. Vannucchi, Daobin Zhou, Mary Frances McMullin, Jianhua Zhong, Robert Peter Gale, Adam J. Mead, John Catalano, William Stevenson, Günther Gastl, Werner Linkesch, Jan Van Droogenbroeck, Philippe Mineur, Vikas Gupta, Andrew Turner, Thomas Nevill, Jianyong Li, Zhixiang Shen, Ting Liu, Dominique Bordessoule, Shanti Natarajan-Amé, Christian Recher, Jean Loup Demory, Richard Schlenk, Martin Griesshammer, Mario Cazzola, Giuseppe Saglio, Giorgina Specchia, Alessandro Rambaldi, Fabrizio Pane, Sonja Zweegman, Peter te Boekhorst, Reinier Raymakers, Kudrat Abdulkadyrov, Manana Sokolova, Galina Salogub, Andrey Zaritskiy, Francisco Cervantes, Juan Carlos Hernández Boluda, Emilio Ojeda, Daniel Tesfa, Lars Nilsson, Mark Drummond, John Reilly, Claire Harrison, Dragana Milojkovic, Candido Rivera, Emmanuel Besa, H. Joachim Deeg, John Mascarenhas, Josef Prchal, Ramon Tiu, Moshe Talpaz, Jen Chin Wang, Raajit Rampal, Damiano Rondelli, Kelly McCaul, Randall Brown, Norio Komatsu, Kazuma Ohyashiki, Kiyoshi Ando, Hiroshi Kawabata, Katsuto Takenaka, Tomoko Hata, James Vardiman, and Leukemia, 2021
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis Sebastiano Rontauroli, Sara Castellano, Paola Guglielmelli, Roberta Zini, Elisa Bianchi, Elena Genovese, Chiara Carretta, Sandra Parenti, Sebastian Fantini, Selene Mallia, Lara Tavernari, Stefano Sartini, Margherita Mirabile, Carmela Mannarelli, Francesca Gesullo, Annalisa Pacilli, Daniela Pietra, Elisa Rumi, Silvia Salmoiraghi, Barbara Mora, Laura Villani, Andrea Grilli, Vittorio Rosti, Giovanni Barosi, Francesco Passamonti, Alessandro Rambaldi, Luca Malcovati, Mario Cazzola, Silvio Bicciato, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini Blood Advances, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial Tiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, Arianna Masciulli, Alessandra Carobbio, Alberto Ferrari, Arianna Ghirardi, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Carmela Mannarelli, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Silvia Betti, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi Lancet Haematology, 2021
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis Gabriella Galatà, Andrés C. García-Montero, Thomas Kristensen, Ahmed A.Z. Dawoud, Javier I. Muñoz-González, Manja Meggendorfer, Paola Guglielmelli, Yvette Hoade, Ivan Alvarez-Twose, Christian Gieger, Konstantin Strauch, Luigi Ferrucci, Toshiko Tanaka, Stefania Bandinelli, Theresia M. Schnurr, Torsten Haferlach, Sigurd Broesby-Olsen, Hanne Vestergaard, Michael Boe Møller, Carsten Bindslev-Jensen, Alessandro M. Vannucchi, Alberto Orfao, Deepti Radia, Andreas Reiter, Andrew J. Chase, Nicholas C.P. Cross, William J. Tapper American Journal of Human Genetics, 2021
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen Patrizia Chiusolo, Stefania Bregante, Sabrina Giammarco, Teresa Lamparelli, Lucia Casarino, Alida Dominietto, Anna Maria Raiola, Elisabetta Metafuni, Carmen Di Grazia, Francesca Gualandi, Federica Sora, Luca Laurenti, Simona Sica, Gianni Barosi, Fabio Guolo, Monica Rossi, Elena Rossi, Alessandro Vannucchi, Alessio Signori, Valerio De Stefano, Andrea Bacigalupo, Emanuele Angelucci American Journal of Hematology, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Alberto Ferrari, Giuseppe Rossi, Elena Elli, Marcio Miguel Andrade-Campos, Mercedes Gasior Kabat, Jean-Jaques Kiladjian, Francesca Palandri, Giulia Benevolo, Valentin Garcia-Gutierrez, Maria Laura Fox, Maria Angeles Foncillas, Carmen Montoya Morcillo, Elisa Rumi, Santiago Osorio, Petros Papadopoulos, Massimiliano Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, Gonzalo Carreno-Tarragona, Marta Anna Sobas, Francesca Lunghi, Andrea Patriarca, Begona Navas Elorza, Anna Angona, Elena Magro Mazo, Steffen Koschmieder, Marco Ruggeri, Beatriz Cuevas, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Blanca Xicoy Cirici, Paola Guglielmelli, Marta Garrote, Daniele Cattaneo, Rosa Daffini, Fabrizio Cavalca, Beatriz Bellosillo, Lina Benajiba, Natalia Curto-Garcia, Marta Bellini, Silvia Betti, Valerio De Stefano, Claire Harrison, Alessandro Rambaldi Leukemia, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Alberto Ferrari, Valeria Cancelli, Elena Maria Elli, Marcio Miguel Andrade-Campos, Mercedes Gasior Kabat, Jean-Jaques Kiladjian, Francesca Palandri, Giulia Benevolo, Valentin Garcia-Gutierrez, Maria Laura Fox, Maria Angeles Foncillas, Carmen Montoya Morcillo, Elisa Rumi, Santiago Osorio, Petros Papadopoulos, Massimiliano Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, Gonzalo Carreno-Tarragona, Marta Anna Sobas, Francesca Lunghi, Andrea Patriarca, Begoña Navas Elorza, Anna Angona, Elena Magro Mazo, Steffen Koschmieder, Giuseppe Carli, Beatriz Cuevas, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Blanca Xicoy Cirici, Paola Guglielmelli, Marta Garrote, Daniele Cattaneo, Rosa Daffini, Fabrizio Cavalca, Beatriz Bellosillo, Lina Benajiba, Natalia Curto-Garcia, Marta Bellini, Silvia Betti, Claire Harrison, Alessandro Rambaldi, Alessandro Maria Vannucchi Blood Cancer Journal, 2021
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection Benedetta Peruzzi, Sara Bencini, Manuela Capone, Alessio Mazzoni, Laura Maggi, Lorenzo Salvati, Anna Vanni, Chiara Orazzini, Carlo Nozzoli, Alessandro Morettini, Loredana Poggesi, Filippo Pieralli, Adriano Peris, Alessandro Bartoloni, Alessandro Maria Vannucchi, Francesco Liotta, Roberto Caporale, Lorenzo Cosmi, Francesco Annunziato Immunology, 2020
Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis Aaron T. Gerds, Michael R. Savona, Bart L. Scott, Moshe Talpaz, Miklos Egyed, Claire N. Harrison, Abdulraheem Yacoub, Alessandro Vannucchi, Adam J. Mead, Jean-Jacques Kiladjian, Jennifer O’Sullivan, Valentin García-Gutiérrez, Prithviraj Bose, Raajit K. Rampal, Carole B. Miller, Jeanne Palmer, Stephen T. Oh, Sarah A. Buckley, Diane R. Mould, Kaori Ito, Shanthakumar Tyavanagimatt, Jennifer A. Smith, Karisse Roman-Torres, Sri Devineni, Adam R. Craig, John O. Mascarenhas Blood Advances, 2020
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey Massimo Breccia, Alfonso Piciocchi, Valerio De Stefano, Guido Finazzi, Alessandra Iurlo, Paola Fazi, Stefano Soddu, Bruno Martino, Francesca Palandri, Sergio Siragusa, Francesco Albano, Francesco Passamonti, Marco Vignetti, Alessandro M. Vannucchi Leukemia, 2020
Genetic lesions disrupting calreticulin 3′-untranslated region in JAK2 mutation-negative polycythemia vera Alberto Quattrocchi, Carlo Maiorca, Monia Billi, Simona Tomassini, Elisabetta De Marinis, Natalia Cenfra, Francesco Equitani, Martina Gentile, Alessia Ceccherelli, Cristina Banella, Sergio Mecarocci, Maria Cristina Scerpa, Stefania Pisanò, Annalisa Pacilli, Claudio Di Cristofano, Massimiliano Mancini, Paola Guglielmelli, Alessandro Maria Vannucchi, Nelida Noguera, Francesco Grignani, Giuseppe Cimino, Clara Nervi American Journal of Hematology, 2020
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study Alessandro Rambaldi, Alessandra Iurlo, Alessandro M. Vannucchi, Richard Noble, Nikolas von Bubnoff, Attilio Guarini, Bruno Martino, Antonio Pezzutto, Giuseppe Carli, Marianna De Muro, Stefania Luciani, Mary Frances McMullin, Nathalie Cambier, Jean-Pierre Marolleau, Ruben A. Mesa, Raoul Tibes, Alessandro Pancrazzi, Francesca Gesullo, Paolo Bettica, Sara Manzoni, Silvia Di Tollo Leukemia, 2020
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia Bianca Rocca, Alberto Tosetto, Silvia Betti, Denise Soldati, Giovanna Petrucci, Elena Rossi, Andrea Timillero, Viviana Cavalca, Benedetta Porro, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Monica Carpenedo, Maria Luigia Randi, Irene Bertozzi, Chiara Paoli, Giorgina Specchia, Alessandra Ricco, Alessandro Maria Vannucchi, Francesco Rodeghiero, Carlo Patrono, Valerio De Stefano Blood, 2020
Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice Veronika Lysenko, Nicole Wildner-Verhey van Wijk, Kathrin Zimmermann, Marie-Christine Weller, Marco Bühler, Mattheus H. E. Wildschut, Patrick Schürch, Christine Fritz, Ulrich Wagner, Laura Calabresi, Bethan Psaila, Richard A. Flavell, Alessandro M. Vannucchi, Adam J. Mead, Peter J. Wild, Stefan Dirnhofer, Markus G. Manz, Alexandre P. A. Theocharides Blood Advances, 2020
β3-Adrenoreceptor Blockade Reduces Hypoxic Myeloid Leukemic Cells Survival and Chemoresistance Maura Calvani, Annalisa Dabraio, Gennaro Bruno, Veronica De Gregorio, Marcella Coronnello, Costanza Bogani, Sara Ciullini, Giancarlo la Marca, Marina Vignoli, Paola Chiarugi, Margherita Nardi, Alessandro Maria Vannucchi, Luca Filippi, Claudio Favre International Journal of Molecular Sciences, 2020
Second cancers in MPN: Survival analysis from an international study Monia Marchetti, Arianna Ghirardi, Arianna Masciulli, Alessandra Carobbio, Francesca Palandri, Nicola Vianelli, Elena Rossi, Silvia Betti, Ambra Di Veroli, Alessandra Iurlo, Daniele Cattaneo, Guido Finazzi, Massimiliano Bonifacio, Luigi Scaffidi, Andrea Patriarca, Elisa Rumi, Ilaria Carola Casetti, Clemency Stephenson, Paola Guglielmelli, Elena Maria Elli, Miroslava Palova, Davide Rapezzi, Daniel Erez, Montse Gomez, Kai Wille, Manuel Perez‐Encinas, Francesca Lunghi, Anna Angona, Maria Laura Fox, Eloise Beggiato, Giulia Benevolo, Giuseppe Carli, Rossella Cacciola, Mary Frances McMullin, Alessia Tieghi, Valle Recasens, Susanne Isfort, Fabrizio Pane, Valerio De Stefano, Martin Griesshammer, Alberto Alvarez‐Larran, Alessandro Maria Vannucchi, Alessandro Rambaldi, Tiziano Barbui American Journal of Hematology, 2020
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis Paola Guglielmelli, Alessandra Carobbio, Elisa Rumi, Valerio De Stefano, Lara Mannelli, Francesco Mannelli, Giada Rotunno, Giacomo Coltro, Silvia Betti, Chiara Cavalloni, Maria Chiara Finazzi, Juergen Thiele, Mario Cazzola, Alessandro Maria Vannucchi, Tiziano Barbui Blood Cancer Journal, 2020
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases Emanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, Massimo Primignani, Maria Luigia Randi, Claudia Santarossa, Elisa Rumi, Francisco Cervantes, Federica Delaini, Alessandra Carobbio, Silvia Betti, Elena Rossi, Noa Lavi, Claire N. Harrison, Natalia Curto‐Garcia, Heinz Gisslinger, Bettina Gisslinger, Giorgina Specchia, Alessandra Ricco, Nicola Vianelli, Nicola Polverelli, Maya Koren‐Michowitz, Marco Ruggeri, Francois Girodon, Martin Ellis, Alessandra Iurlo, Francesco Mannelli, Lara Mannelli, Benedetta Sordi, Giuseppe Gaetano Loscocco, Mario Cazzola, Valerio De Stefano, Tiziano Barbui, Ayalew Tefferi, Alessandro Maria Vannucchi American Journal of Hematology, 2020
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study Valerio De Stefano, Arianna Ghirardi, Arianna Masciulli, Alessandra Carobbio, Francesca Palandri, Nicola Vianelli, Elena Rossi, Silvia Betti, Ambra Di Veroli, Alessandra Iurlo, Daniele Cattaneo, Guido Finazzi, Massimiliano Bonifacio, Luigi Scaffidi, Andrea Patriarca, Elisa Rumi, Ilaria Carola Casetti, Clemency Stephenson, Paola Guglielmelli, Elena Maria Elli, Miroslava Palova, Davide Rapezzi, Daniel Erez, Montse Gomez, Kai Wille, Manuel Perez-Encinas, Francesca Lunghi, Anna Angona, Maria Laura Fox, Eloise Beggiato, Giulia Benevolo, Giuseppe Carli, Rossella Cacciola, Mary Frances McMullin, Alessia Tieghi, Valle Recasens, Susanne Isfort, Monia Marchetti, Martin Griesshammer, Alberto Alvarez-Larran, Alessandro Maria Vannucchi, Alessandro Rambaldi, Tiziano Barbui Blood, 2020
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Daniela Barraco, Alessandro Rambaldi, Marianna Caramella, Rami S. Komrokji, Jean‐Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Francesco Albano, Giulia Benevolo, Chiara Cavalloni, Silvia Uccella, Raffaella Accetta, Claudia Siracusa, Stefania Agnoli, Michele Merli, Tiziano Barbui, Lorenza Bertù, Mario Cazzola, Alessandro M. Vannucchi, Francesco Passamonti American Journal of Hematology, 2020
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea Abdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, Josef T. Prchal, Dmitry Berenzon, Maria R. Baer, Ellen Ritchie, Richard T. Silver, Craig Kessler, Elliott Winton, Maria Chiara Finazzi, Alessandro Rambaldi, Alessandro M. Vannucchi, David Leibowitz, Damiano Rondelli, Murat O. Arcasoy, Rosalind Catchatourian, Joseph Vadakara, Vittorio Rosti, Elizabeth Hexner, Marina Kremyanskaya, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, Noushin Farnoud, Elli Papaemmanuil, Mohamed Salama, Rona Singer-Weinberg, Raajit Rampal, Judith D. Goldberg, Tiziano Barbui, Ruben Mesa, Amylou C. Dueck, Ronald Hoffman Blood, 2019
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative Giuseppe G. Loscocco, Francesco Mannelli, Paola Guglielmelli, Chiara Paoli, Ilaria Marone, Rosalba Cucci, Giacomo Coltro, Benedetta Sordi, Francesco Albano, Massimo Breccia, Valerio De Stefano, Guido Finazzi, Alessandra Iurlo, Bruno Martino, Francesca Palandri, Francesco Passamonti, Sergio Siragusa, Lara Mannelli, Duccio Fantoni, Paola Fazi, Sergio Amadori, Marco Vignetti, Tiziano Barbui, Alessandro M. Vannucchi American Journal of Hematology, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study Tiziano Barbui, Arianna Ghirardi, Arianna Masciulli, Alessandra Carobbio, Francesca Palandri, Nicola Vianelli, Valerio De Stefano, Silvia Betti, Ambra Di Veroli, Alessandra Iurlo, Daniele Cattaneo, Federica Delaini, Massimiliano Bonifacio, Luigi Scaffidi, Andrea Patriarca, Elisa Rumi, Ilaria Carola Casetti, Clemency Stephenson, Paola Guglielmelli, Elena Maria Elli, Miroslava Palova, Laura Bertolotti, Daniel Erez, Montse Gomez, Kai Wille, Manuel Perez-Encinas, Francesca Lunghi, Anna Angona, Maria Laura Fox, Eloise Beggiato, Giulia Benevolo, Giuseppe Carli, Rossella Cacciola, Mary Frances McMullin, Alessia Tieghi, Valle Recasens, Monia Marchetti, Martin Griesshammer, Alberto Alvarez-Larran, Alessandro Maria Vannucchi, Guido Finazzi Leukemia, 2019
Circ RNAs are here to stay: A perspective on the MLL recombinome Anna Dal Molin, Silvia Bresolin, Enrico Gaffo, Caterina Tretti, Elena Boldrin, Lueder H. Meyer, Paola Guglielmelli, Alessandro M. Vannucchi, Geertruij te Kronnie, Stefania Bortoluzzi Frontiers in Genetics, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients Barbara Mora, Elisa Rumi, Paola Guglielmelli, Daniela Barraco, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Toni Giorgino, Francesco Passamonti Cancer Medicine, 2019
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea Annalisa Pacilli, Giada Rotunno, Carmela Mannarelli, Tiziana Fanelli, Alessandro Pancrazzi, Elisa Contini, Francesco Mannelli, Francesca Gesullo, Niccolò Bartalucci, Giuditta Corbizi Fattori, Chiara Paoli, Alessandro M. Vannucchi, Paola Guglielmelli Blood Cancer Journal, 2018
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis Chiara Rossi, Roberta Zini, Sebastiano Rontauroli, Samantha Ruberti, Zelia Prudente, Greta Barbieri, Elisa Bianchi, Simona Salati, Elena Genovese, Niccolò Bartalucci, Paola Guglielmelli, Enrico Tagliafico, Vittorio Rosti, Giovanni Barosi, Alessandro M. Vannucchi, Rossella Manfredini, the AGIMM (AIRC‐Gruppo Italiano Malattie Mieloproliferative) investigators Molecular Oncology, 2018
Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling, human myelofibrosis Anna Chorzalska, John Morgan, Nagib Ahsan, Diana O. Treaba, Adam J. Olszewski, Max Petersen, Nathan Kingston, Yan Cheng, Kara Lombardo, Christoph Schorl, Xiaoqing Yu, Roberta Zini, Annalisa Pacilli, Alexander Tepper, Jillian Coburn, Anita Hryniewicz-Jankowska, Ting C. Zhao, Elena Oancea, John L. Reagan, Olin Liang, Leszek Kotula, Peter J. Quesenberry, Philip A. Gruppuso, Rossella Manfredini, Alessandro Maria Vannucchi, Patrycja M. Dubielecka Blood, 2018
Classification and personalized prognosis in myeloproliferative neoplasms Jacob Grinfeld, Jyoti Nangalia, E. Joanna Baxter, David C. Wedge, Nicos Angelopoulos, Robert Cantrill, Anna L. Godfrey, Elli Papaemmanuil, Gunes Gundem, Cathy MacLean, Julia Cook, Laura O’Neil, Sarah O’Meara, Jon W. Teague, Adam P. Butler, Charlie E. Massie, Nicholas Williams, Francesca L. Nice, Christen L. Andersen, Hans C. Hasselbalch, Paola Guglielmelli, Mary F. McMullin, Alessandro M. Vannucchi, Claire N. Harrison, Moritz Gerstung, Anthony R. Green, Peter J. Campbell New England Journal of Medicine, 2018
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project Daniela Barraco, Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Michele Merli, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Toni Giorgino, Alessandro Maria Vannucchi, Francesco Passamonti Blood Cancer Journal, 2018
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project Barbara Mora, Toni Giorgino, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela Barraco, Michele Merli, Daniela Pietra, Rosario Casalone, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Francesco Passamonti Haematologica, 2018
GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis Ayalew Tefferi, Paola Guglielmelli, Maura Nicolosi, Francesco Mannelli, Mythri Mudireddy, Niccolo Bartalucci, Christy M. Finke, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Kebede H. Begna, Naseema Gangat, Animesh Pardanani, Alessandro M. Vannucchi Leukemia, 2018
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts Ayalew Tefferi, Mythri Mudireddy, Francesco Mannelli, Kebede H. Begna, Mrinal M. Patnaik, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Meera Yogarajah, Valerio De Stefano, Francesco Passamonti, Vittorio Rosti, Maria Chiara Finazzi, Alessandro Rambaldi, Alberto Bosi, Paola Guglielmelli, Animesh Pardanani, Alessandro M. Vannucchi Leukemia, 2018
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, Francesco Passamonti, Richard T. Silver, Ronald Hoffman, Srdan Verstovsek, Ruben Mesa, Jean-Jacques Kiladjian, Rȕdiger Hehlmann, Andreas Reiter, Francisco Cervantes, Claire Harrison, Mary Frances Mc Mullin, Hans Carl Hasselbalch, Steffen Koschmieder, Monia Marchetti, Andrea Bacigalupo, Guido Finazzi, Nicolaus Kroeger, Martin Griesshammer, Gunnar Birgegard, Giovanni Barosi Leukemia, 2018
The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells Maria Antonietta Avanzini, Vittorio Abbonante, Paolo Catarsi, Irene Dambruoso, Melissa Mantelli, Valentina Poletto, Elisa Lenta, Paola Guglielmelli, Stefania Croce, Lorenzo Cobianchi, Basilio Jemos, Rita Campanelli, Elisa Bonetti, Christian Andrea Di Buduo, Silvia Salmoiraghi, Laura Villani, Margherita Massa, Marina Boni, Rita Zappatore, Alessandra Iurlo, Alessandro Rambaldi, Alessandro Maria Vannucchi, Paolo Bernasconi, Alessandra Balduini, Giovanni Barosi, Vittorio Rosti, on behalf of the AGIMM Investigators American Journal of Hematology, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms Valerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, Paola Guglielmelli, Alessandra Iurlo, Maria Chiara Finazzi, Elisa Rumi, Francisco Cervantes, Elena Maria Elli, Maria Luigia Randi, Martin Griesshammer, Francesca Palandri, Massimiliano Bonifacio, Juan-Carlos Hernandez-Boluda, Rossella Cacciola, Palova Miroslava, Giuseppe Carli, Eloise Beggiato, Martin H. Ellis, Caterina Musolino, Gianluca Gaidano, Davide Rapezzi, Alessia Tieghi, Francesca Lunghi, Giuseppe Gaetano Loscocco, Daniele Cattaneo, Agostino Cortelezzi, Silvia Betti, Elena Rossi, Guido Finazzi, Bruno Censori, Mario Cazzola, Marta Bellini, Eduardo Arellano-Rodrigo, Irene Bertozzi, Parvis Sadjadian, Nicola Vianelli, Luigi Scaffidi, Montse Gomez, Emma Cacciola, Alessandro M. Vannucchi, Tiziano Barbui Blood Cancer Journal, 2018
MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis Paola Guglielmelli, Terra L. Lasho, Giada Rotunno, Mythri Mudireddy, Carmela Mannarelli, Maura Nicolosi, Annalisa Pacilli, Animesh Pardanani, Elisa Rumi, Vittorio Rosti, Curtis A. Hanson, Francesco Mannelli, Rhett P. Ketterling, Naseema Gangat, Alessandro Rambaldi, Francesco Passamonti, Giovanni Barosi, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi, Ayalew Tefferi Journal of Clinical Oncology, 2018
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients , S Ruberti, E Bianchi, P Guglielmelli, S Rontauroli, G Barbieri, L Tavernari, T Fanelli, R Norfo, V Pennucci, G Corbizi Fattori, C Mannarelli, N Bartalucci, B Mora, L Elli, M A Avanzini, C Rossi, S Salmoiraghi, R Zini, S Salati, Z Prudente, V Rosti, F Passamonti, A Rambaldi, S Ferrari, E Tagliafico, A M Vannucchi, R Manfredini Leukemia, 2018
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs Allison H. Scotch, Heidi Kosiorek, Robyn Scherber, Amylou C. Dueck, Stefanie Slot, Sonja Zweegman, Peter A.W.te Boekhorst, Suzan Commandeur, Harry Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Döhner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Chiara Paoli, Francesco Passamonti, Bjorn Andreasson, Maria L. Ferrari, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Jean-Jacques Kiladjian, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa, Holly L. Geyer Leukemia Research, 2017
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera Tiziano Barbui, Alessandro M. Vannucchi, Alessandra Carobbio, Elisa Rumi, Guido Finazzi, Heinz Gisslinger, Marco Ruggeri, Maria Luigia Randi, Mario Cazzola, Alessandro Rambaldi, Bettina Gisslinger, Lisa Pieri, Juergen Thiele, Animesh Pardanani, Ayalew Tefferi American Journal of Hematology, 2017
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group Holly L. Geyer, Heidi Kosiorek, Amylou C. Dueck, Robyn Scherber, Stefanie Slot, Sonja Zweegman, Peter AW te Boekhorst, Zhenya Senyak, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Döhner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Chiara Paoli, Francesco Passamonti, Bjorn Andreasson, Maria L Ferrari, Alessandro Rambaldi, Jan Samuelsson, Keith Cannon, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Jean-Jacques Kiladjian, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa Haematologica, 2017
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients V De Stefano, A M Vannucchi, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, M L Randi, L Pieri, E Rossi, P Guglielmelli, S Betti, E Elli, M C Finazzi, G Finazzi, E Zetterberg, N Vianelli, G Gaidano, I Nichele, D Cattaneo, M Palova, M H Ellis, E Cacciola, A Tieghi, J C Hernandez-Boluda, E Pungolino, G Specchia, D Rapezzi, A Forcina, C Musolino, A Carobbio, M Griesshammer, T Barbui Blood Cancer Journal, 2016
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients Paola Guglielmelli, Giada Rotunno, Annalisa Pacilli, Elisa Rumi, Vittorio Rosti, Federica Delaini, Margherita Maffioli, Tiziana Fanelli, Alessandro Pancrazzi, Lisa Pieri, Rajmonda Fjerza, Daniela Pietra, Daniela Cilloni, Emanuela Sant'Antonio, Silvia Salmoiraghi, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi American Journal of Hematology, 2016
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation A. Alvarez-Larran, A. Pereira, P. Guglielmelli, J. C. Hernandez-Boluda, E. Arellano-Rodrigo, F. Ferrer-Marin, A. Samah, M. Griesshammer, A. Kerguelen, B. Andreasson, C. Burgaleta, J. Schwarz, V. Garcia-Gutierrez, R. Ayala, P. Barba, M. T. Gomez-Casares, C. Paoli, B. Drexler, S. Zweegman, M. F. McMullin, J. Samuelsson, C. Harrison, F. Cervantes, A. M. Vannucchi, C. Besses Haematologica, 2016
Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis Paola Guglielmelli, Giada Rotunno, Costanza Bogani, Carmela Mannarelli, Laura Giunti, Aldesia Provenzano, Sabrina Giglio, Matthew Squires, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Alessandro M. Vannucchi, the COMFORT‐II Investigators British Journal of Haematology, 2016
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis Rita Campanelli, Gabriela Fois, Paolo Catarsi, Valentina Poletto, Laura Villani, Benedetta Gaia Erba, Luigi Maddaluno, Basilio Jemos, Silvia Salmoiraghi, Paola Guglielmelli, Vittorio Abbonante, Christian Andrea Di Buduo, Alessandra Balduini, Alessandra Iurlo, Giovanni Barosi, Vittorio Rosti, Margherita Massa, AGIMM Investigators Plos One, 2016
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis Simona Salati, Roberta Zini, Simona Nuzzo, Paola Guglielmelli, Valentina Pennucci, Zelia Prudente, Samantha Ruberti, Sebastiano Rontauroli, Ruggiero Norfo, Elisa Bianchi, Costanza Bogani, Giada Rotunno, Tiziana Fanelli, Carmela Mannarelli, Vittorio Rosti, Silvia Salmoiraghi, Daniela Pietra, Sergio Ferrari, Giovanni Barosi, Alessandro Rambaldi, Mario Cazzola, Silvio Bicciato, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini, and International Journal of Cancer, 2016
The european hematology association roadmap for european hematology research: A consensus document A. Engert, C. Balduini, A. Brand, B. Coiffier, C. Cordonnier, H. Dohner, T. D. de Wit, S. Eichinger, W. Fibbe, T. Green, F. de Haas, A. Iolascon, T. Jaffredo, F. Rodeghiero, G. Salles, J. J. Schuringa, the other authors of the EHA Roadmap for European Hematology Research, J. J. Schuringa, T. Jaffredo, B. Coiffier, G. Salles, H. Dohner, A. Iolascon, C. Balduini, S. Eichinger, A. Brand, C. Cordonnier, W. Fibbe Haematologica, 2016
Symptomatic profiles of patients with polycythemia vera: Implications of inadequately controlled disease Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Döhner, Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Norman Maldonado, Giovanni Barosi, Maria L. Ferrari, Robert Peter Gale, Gunnar Birgegard, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Peter A.W. te Boekhorst, Suzan Commandeur, Harry Schouten, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Thomas Lehmann, Zhenya Senyak, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, Ruben A. Mesa Journal of Clinical Oncology, 2016
STAT1 activation in association with JAK2 exon 12 mutations A. L. Godfrey, E. Chen, C. E. Massie, Y. Silber, F. Pagano, B. Bellosillo, P. Guglielmelli, C. N. Harrison, J. T. Reilly, F. Stegelmann, F. Bijou, E. Lippert, J.-M. Boiron, K. Dohner, A. M. Vannucchi, C. Besses, A. R. Green Haematologica, 2016
Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial Animesh Pardanani, Claire Harrison, Jorge E. Cortes, Francisco Cervantes, Ruben A. Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Eric Jourdan, Alessandro M. Vannucchi, Mark W. Drummond, Mindaugas Jurgutis, Kazimierz Kuliczkowski, Emanuil Gheorghita, Francesco Passamonti, Frank Neumann, Abhay Patki, Guozhi Gao, Ayalew Tefferi JAMA Oncology, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms William Tapper, Amy V. Jones, Robert Kralovics, Ashot S. Harutyunyan, Katerina Zoi, William Leung, Anna L. Godfrey, Paola Guglielmelli, Alison Callaway, Daniel Ward, Paula Aranaz, Helen E. White, Katherine Waghorn, Feng Lin, Andrew Chase, E. Joanna Baxter, Cathy Maclean, Jyoti Nangalia, Edwin Chen, Paul Evans, Michael Short, Andrew Jack, Louise Wallis, David Oscier, Andrew S. Duncombe, Anna Schuh, Adam J. Mead, Michael Griffiths, Joanne Ewing, Rosemary E. Gale, Susanne Schnittger, Torsten Haferlach, Frank Stegelmann, Konstanze Döhner, Harald Grallert, Konstantin Strauch, Toshiko Tanaka, Stefania Bandinelli, Andreas Giannopoulos, Lisa Pieri, Carmela Mannarelli, Heinz Gisslinger, Giovanni Barosi, Mario Cazzola, Andreas Reiter, Claire Harrison, Peter Campbell, Anthony R. Green, Alessandro Vannucchi, Nicholas C.P. Cross Nature Communications, 2015
Effect of mutation order on myeloproliferative neoplasms Christina A. Ortmann, David G. Kent, Jyoti Nangalia, Yvonne Silber, David C. Wedge, Jacob Grinfeld, E. Joanna Baxter, Charles E. Massie, Elli Papaemmanuil, Suraj Menon, Anna L. Godfrey, Danai Dimitropoulou, Paola Guglielmelli, Beatriz Bellosillo, Carles Besses, Konstanze Döhner, Claire N. Harrison, George S. Vassiliou, Alessandro Vannucchi, Peter J. Campbell, Anthony R. Green New England Journal of Medicine, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia vera Alessandro M. Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Ruben Mesa, Shui He, Mark M. Jones, William Garrett, Jingjin Li, Ulrich Pirron, Dany Habr, Srdan Verstovsek New England Journal of Medicine, 2015
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study Ida Martinelli, Valerio De Stefano, Alessandra Carobbio, Maria L. Randi, Claudia Santarossa, Alessandro Rambaldi, Maria C. Finazzi, Francisco Cervantes, Eduardo Arellano‐Rodrigo, Serena Rupoli, Lucia Canafoglia, Alessia Tieghi, Luca Facchini, Silvia Betti, Alessandro M. Vannucchi, Lisa Pieri, Rossella Cacciola, Emma Cacciola, Agostino Cortelezzi, Alessandra Iurlo, Enrico M. Pogliani, Elena M. Elli, Antonio Spadea, Tiziano Barbui American Journal of Hematology, 2014
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+cells: Role of miR-155/JARID2 axis in abnormal megakaryopoiesis Ruggiero Norfo, Roberta Zini, Valentina Pennucci, Elisa Bianchi, Simona Salati, Paola Guglielmelli, Costanza Bogani, Tiziana Fanelli, Carmela Mannarelli, Vittorio Rosti, Daniela Pietra, Silvia Salmoiraghi, Andrea Bisognin, Samantha Ruberti, Sebastiano Rontauroli, Giorgia Sacchi, Zelia Prudente, Giovanni Barosi, Mario Cazzola, Alessandro Rambaldi, Stefania Bortoluzzi, Sergio Ferrari, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini Blood, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis Elisa Rumi, Daniela Pietra, Cristiana Pascutto, Paola Guglielmelli, Alejandra Martínez-Trillos, Ilaria Casetti, Dolors Colomer, Lisa Pieri, Marta Pratcorona, Giada Rotunno, Emanuela Sant’Antonio, Marta Bellini, Chiara Cavalloni, Carmela Mannarelli, Chiara Milanesi, Emanuela Boveri, Virginia Ferretti, Cesare Astori, Vittorio Rosti, Francisco Cervantes, Giovanni Barosi, Alessandro M. Vannucchi, Mario Cazzola Blood, 2014
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis Damiano Rondelli, Judith D. Goldberg, Luis Isola, Leah S. Price, Tsiporah B. Shore, Michael Boyer, Andrea Bacigalupo, Alessandro Rambaldi, Marco Scarano, Rebecca B. Klisovic, Vikas Gupta, Bjorn Andreasson, John Mascarenhas, Meir Wetzler, Alessandro M. Vannucchi, Josef T. Prchal, Vesna Najfeld, Attilio Orazi, Rona S. Weinberg, Crystal Miller, Giovanni Barosi, Lewis R. Silverman, Giuseppe Prosperini, Roberto Marchioli, Ronald Hoffman Blood, 2014
Essential Thrombocytosis Paola Guglielmelli, Alessandro M. Vannucchi Cancer Consult Expertise for Clinical Practice, 2014
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients Holly L. Geyer, Robyn M. Scherber, Amylou C. Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Döhner, Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, Gunnar Birgegard, Ruben A. Mesa Blood, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study Paola Guglielmelli, Flavia Biamonte, Giada Rotunno, Valentina Artusi, Lucia Artuso, Isabella Bernardis, Elena Tenedini, Lisa Pieri, Chiara Paoli, Carmela Mannarelli, Rajmonda Fjerza, Elisa Rumi, Viktoriya Stalbovskaya, Matthew Squires, Mario Cazzola, Rossella Manfredini, Claire Harrison, Enrico Tagliafico, Alessandro M. Vannucchi Blood, 2014
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia Maria Luigia Randi, Irene Bertozzi, Elisa Rumi, Chiara Elena, Guido Finazzi, Nicola Vianelli, Nicola Polverelli, Marco Ruggeri, Alessandro Maria Vannucchi, Elisabetta Antonioli, Federico Lussana, Alessia Tieghi, Alessandra Iurlo, Elena Elli, Marco Ruella, Fabrizio Fabris, Mario Cazzola, Tiziano Barbui American Journal of Hematology, 2014
Masked polycythemia vera diagnosed according to WHO and BCSH classification Tiziano Barbui, Jürgen Thiele, Alessandra Carobbio, Heinz Gisslinger, Guido Finazzi, Elisa Rumi, Maria Luigia Randi, Alessandro M. Vannucchi, Bettina Gisslinger, Leonhard Müllauer, Marco Ruggeri, Alessandro Rambaldi, Ayalew Tefferi American Journal of Hematology, 2014
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies R. A. Mesa, J.-J. Kiladjian, S. Verstovsek, H. K. Al-Ali, J. Gotlib, H. Gisslinger, R. Levy, A. Siulnik, V. Gupta, M. Khan, J. F. DiPersio, M. McQuitty, J. V. Catalano, D. S. Hunter, L. Knoops, M. Deininger, F. Cervantes, C. Miller, A. M. Vannucchi, R. T. Silver, T. Barbui, M. Talpaz, G. Barosi, E. F. Winton, E. Mendeson, J. H. Harvey, M. O. Arcasoy, E. Hexner, R. M. Lyons, R. Paquette, A. Raza, W. Sun, V. Sandor, H. M. Kantarjian, C. Harrison Haematologica, 2014
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients Ayalew Tefferi, Emnet A. Wassie, Paola Guglielmelli, Naseema Gangat, Alem A. Belachew, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Animesh Pardanani, Alexandra P. Wolanskyj, Margherita Maffioli, Rosario Casalone, Annalisa Pacilli, Alessandro M. Vannucchi, Francesco Passamonti American Journal of Hematology, 2014
Masked polycythemia Vera (mPV): Results of an international study Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Guido Finazzi, Alessandra Carobbio, Elisa Rumi, Maria Luigia Randi, Irene Betozzi, Alessandro M. Vannucchi, Lisa Pieri, Valentina Carrai, Bettina Gisslinger, Leonhard Müllauer, Marco Ruggeri, Alessandro Rambaldi, Ayalew Tefferi American Journal of Hematology, 2014
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms on behalf of AGIMM investigators, E Tenedini, I Bernardis, V Artusi, L Artuso, E Roncaglia, P Guglielmelli, L Pieri, C Bogani, F Biamonte, G Rotunno, C Mannarelli, E Bianchi, A Pancrazzi, T Fanelli, G Malagoli Tagliazucchi, S Ferrari, R Manfredini, A M Vannucchi, E Tagliafico Leukemia, 2014
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2 Thorsten Klampfl, Jelena D. Milosevic, Ana Puda, Andreas Schönegger, Klaudia Bagienski, Tiina Berg, Ashot S. Harutyunyan, Bettina Gisslinger, Elisa Rumi, Luca Malcovati, Daniela Pietra, Chiara Elena, Matteo Giovanni Della Porta, Lisa Pieri, Paola Guglielmelli, Christoph Bock, Michael Doubek, Dana Dvorakova, Nada Suvajdzic, Dragica Tomin, Natasa Tosic, Zdenek Racil, Michael Steurer, Sonja Pavlovic, Alessandro M. Vannucchi, Mario Cazzola, Heinz Gisslinger, Robert Kralovics Plos One, 2013
Mutations and prognosis in primary myelofibrosis A M Vannucchi, T L Lasho, P Guglielmelli, F Biamonte, A Pardanani, A Pereira, C Finke, J Score, N Gangat, C Mannarelli, R P Ketterling, G Rotunno, R A Knudson, M C Susini, R R Laborde, A Spolverini, A Pancrazzi, L Pieri, R Manfredini, E Tagliafico, R Zini, A Jones, K Zoi, A Reiter, A Duncombe, D Pietra, E Rumi, F Cervantes, G Barosi, M Cazzola, N C P Cross, A Tefferi Leukemia, 2013
The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis Maria C. Susini, Paola Guglielmelli, Ambra Spolverini, Flavia Biamonte, Carmela Mannarelli, Giovanni Barosi, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Francisco Cervantes, Mario Cazzola, Nick Cross, Alessandro M. Vannucchi, the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators British Journal of Haematology, 2013
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation Vittorio Rosti, Laura Villani, Roberta Riboni, Valentina Poletto, Elisa Bonetti, Lorenzo Tozzi, Gaetano Bergamaschi, Paolo Catarsi, Elena Dallera, Francesca Novara, Margherita Massa, Rita Campanelli, Gabriela Fois, Benedetta Peruzzi, Marco Lucioni, Paola Guglielmelli, Alessandro Pancrazzi, Giacomo Fiandrino, Orsetta Zuffardi, Umberto Magrini, Marco Paulli, Alessandro M. Vannucchi, Giovanni Barosi Blood, 2013
Cardiovascular events and intensity of treatment in polycythemia vera Roberto Marchioli, Guido Finazzi, Giorgina Specchia, Rossella Cacciola, Riccardo Cavazzina, Daniela Cilloni, Valerio De Stefano, Elena Elli, Alessandra Iurlo, Roberto Latagliata, Francesca Lunghi, Monia Lunghi, Rosa Maria Marfisi, Pellegrino Musto, Arianna Masciulli, Caterina Musolino, Nicola Cascavilla, Giovanni Quarta, Maria Luigia Randi, Davide Rapezzi, Marco Ruggeri, Elisa Rumi, Anna Rita Scortechini, Simone Santini, Marco Scarano, Sergio Siragusa, Antonio Spadea, Alessia Tieghi, Emanuele Angelucci, Giuseppe Visani, Alessandro Maria Vannucchi, Tiziano Barbui New England Journal of Medicine, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 J. Nangalia, C.E. Massie, E.J. Baxter, F.L. Nice, G. Gundem, D.C. Wedge, E. Avezov, J. Li, K. Kollmann, D.G. Kent, A. Aziz, A.L. Godfrey, J. Hinton, I. Martincorena, P. Van Loo, A.V. Jones, P. Guglielmelli, P. Tarpey, H.P. Harding, J.D. Fitzpatrick, C.T. Goudie, C.A. Ortmann, S.J. Loughran, K. Raine, D.R. Jones, A.P. Butler, J.W. Teague, S. O'Meara, S. McLaren, M. Bianchi, Y. Silber, D. Dimitropoulou, D. Bloxham, L. Mudie, M. Maddison, B. Robinson, C. Keohane, C. Maclean, K. Hill, K. Orchard, S. Tauro, M.-Q. Du, M. Greaves, D. Bowen, B.J.P. Huntly, C.N. Harrison, N.C.P. Cross, D. Ron, A.M. Vannucchi, E. Papaemmanuil, P.J. Campbell, A.R. Green New England Journal of Medicine, 2013
Molecular genetics in diagnosis and prognosis of philadelphia chromosome negative myeloproliferative neoplasms molecular genetics in MPNS Onkologie, 2012
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, Jean-Jacques Kiladjian, Stefanie Slot, Sonja Zweegman, Peter A.W. te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Doehner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria L. Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Ayalew Tefferi, Ruben A. Mesa Journal of Clinical Oncology, 2012
Clinical significance of genetic aberrations in secondary acute myeloid leukemia Jelena D. Milosevic, Ana Puda, Luca Malcovati, Tiina Berg, Michael Hofbauer, Alexey Stukalov, Thorsten Klampfl, Ashot S. Harutyunyan, Heinz Gisslinger, Bettina Gisslinger, Tatiana Burjanivova, Elisa Rumi, Daniela Pietra, Chiara Elena, Alessandro M. Vannucchi, Michael Doubek, Dana Dvorakova, Blanka Robesova, Rotraud Wieser, Elisabeth Koller, Nada Suvajdzic, Dragica Tomin, Natasa Tosic, Jacques Colinge, Zdenek Racil, Michael Steurer, Sonja Pavlovic, Mario Cazzola, Robert Kralovics American Journal of Hematology, 2012
Improving survival trends in primary myelofibrosis: An international study Francisco Cervantes, Brigitte Dupriez, Francesco Passamonti, Alessandro M. Vannucchi, Enrica Morra, John T. Reilly, Jean-Loup Demory, Elisa Rumi, Paola Guglielmelli, Elisa Roncoroni, Ayalew Tefferi, Arturo Pereira Journal of Clinical Oncology, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN Elisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, MariaChiara Finazzi, Elisa Rumi, Vincenzo Martinelli, Nicola Vianelli, Maria Luigia Randi, Irene Bertozzi, Valerio De Stefano, Tommaso Za, Elena Rossi, Marco Ruggeri, Elena Elli, Rossella Cacciola, Emma Cacciola, Enrico Pogliani, Francesco Rodeghiero, Michele Baccarani, Francesco Passamonti, Guido Finazzi, Alessandro Rambaldi, Alberto Bosi, Mario Cazzola, Tiziano Barbui, Alessandro M. Vannucchi, On behalf of the AGIMM Investigators American Journal of Hematology, 2012
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome Tiziano Barbui, Jürgen Thiele, Francesco Passamonti, Elisa Rumi, Emanuela Boveri, Maria Luigia Randi, Irene Bertozzi, Filippo Marino, Alessandro M. Vannucchi, Lisa Pieri, Giada Rotunno, Heinz Gisslinger, Bettina Gisslinger, Leonhard Müllauer, Guido Finazzi, Alessandra Carobbio, Andrea Gianatti, Marco Ruggeri, Ilaria Nichele, Emanuele D'Amore, Alessandro Rambaldi, Ayalew Tefferi Blood, 2012
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis Claire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richard Levy, Laurent Knoops, Francisco Cervantes, Alessandro M. Vannucchi, Tiziano Barbui, Giovanni Barosi New England Journal of Medicine, 2012
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies Ana Puda, Jelena D. Milosevic, Tiina Berg, Thorsten Klampfl, Ashot S. Harutyunyan, Bettina Gisslinger, Elisa Rumi, Daniela Pietra, Luca Malcovati, Chiara Elena, Michael Doubek, Michael Steurer, Natasa Tosic, Sonja Pavlovic, Paola Guglielmelli, Lisa Pieri, Alessandro M. Vannucchi, Heinz Gisslinger, Mario Cazzola, Robert Kralovics American Journal of Hematology, 2012
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia Alessandra Carobbio, Guido Finazzi, Juergen Thiele, Hans‐Michael Kvasnicka, Francesco Passamonti, Elisa Rumi, Marco Ruggeri, Francesco Rodeghiero, Maria Luigia Randi, Irene Bertozzi, Alessandro M. Vannucchi, Elisabetta Antonioli, Heinz Gisslinger, Veronika Buxhofer‐Ausch, Naseema Gangat, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui American Journal of Hematology, 2012
RBC-transfusion guidelines update R.P. Gale, G. Barosi, T. Barbui, F. Cervantes, K. Dohner, B. Dupriez, V. Gupta, C. Harrison, R. Hoffman, J.J. Kiladjian, R. Mesa, M.F. Mc Mullin, F. Passamonti, V. Ribrag, G. Roboz, G. Saglio, A. Vannucchi, S. Verstovsek Leukemia Research, 2012
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia Luigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, Potito Rosario Scalzulli, Rosanna Ciancia, Monia Lunghi, Emma Cacciola, Rossella Cacciola, Anna Candoni, Monica Crugnola, Katia Codeluppi, Emilio Usala, Giorgina Specchia, Vincenzo Martinelli, Fausto Palmieri, Ivana Pierri, Anna Marina Liberati, Alessandra Iurlo, Alberto Grossi, Alessandro M. Vannucchi, Nicola Vianelli, Maria Gabriella Mazzucconi Leukemia Research, 2011
EZH2 mutational status predicts poor survival in myelofibrosis Paola Guglielmelli, Flavia Biamonte, Joannah Score, Claire Hidalgo-Curtis, Francisco Cervantes, Margherita Maffioli, Tiziana Fanelli, Thomas Ernst, Nils Winkelman, Amy V. Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Laura Villani, Alberto Bosi, Giovanni Barosi, Nicholas C. P. Cross, Alessandro M. Vannucchi Blood, 2011
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, Roberto Marchioli, Arianna Masciulli, Lorenzo Tozzi, Flavia Biamonte, Niccolò Bartalucci, Elisabetta Gattoni, Maria Letizia Lupo, Guido Finazzi, Alessandro Pancrazzi, Elisabetta Antonioli, Maria Chiara Susini, Lisa Pieri, Elisa Malevolti, Emilio Usala, Ubaldo Occhini, Alberto Grossi, Silvia Caglio, Simona Paratore, Alberto Bosi, Tiziano Barbui, Alessandro M. Vannucchi, on behalf of the AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators Blood, 2011
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: A international study Tiziano Barbui, Juergen Thiele, Francesco Passamonti, Elisa Rumi, Emanuela Boveri, Marco Ruggeri, Francesco Rodeghiero, Emanuele S.G. d'Amore, Maria Luigia Randi, Irene Bertozzi, Filippo Marino, Alessandro M. Vannucchi, Elisabetta Antonioli, Valentina Carrai, Heinz Gisslinger, Veronika Buxhofer-Ausch, Leonhard Müllauer, Alessandra Carobbio, Andrea Gianatti, Naseema Gangat, Curtis A. Hanson, Ayalew Tefferi Journal of Clinical Oncology, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression Thorsten Klampfl, Ashot Harutyunyan, Tiina Berg, Bettina Gisslinger, Martin Schalling, Klaudia Bagienski, Damla Olcaydu, Francesco Passamonti, Elisa Rumi, Daniela Pietra, Roland Jäger, Lisa Pieri, Paola Guglielmelli, Ilaria Iacobucci, Giovanni Martinelli, Mario Cazzola, Alessandro M. Vannucchi, Heinz Gisslinger, Robert Kralovics Blood, 2011
FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis Christophe Desterke, Chrystele Bilhou-Nabéra, Bernadette Guerton, Christophe Martinaud, Carole Tonetti, Denis Clay, Paola Guglielmelli, Alessandro Vannucchi, Dominique Bordessoule, Hans Hasselbalch, Brigitte Dupriez, Nassima Benzoubir, Marie-Françoise Bourgeade, Olivier Pierre-Louis, Vladimir Lazar, William Vainchenker, Annelise Bennaceur-Griscelli, Heinz Gisslinger, Stéphane Giraudier, Marie-Caroline Le Bousse-Kerdilès Cancer Research, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations Francesco Passamonti, Chiara Elena, Susanne Schnittger, Radek C. Skoda, Anthony R. Green, François Girodon, Jean-Jacques Kiladjian, Mary Frances McMullin, Marco Ruggeri, Carles Besses, Alessandro M. Vannucchi, Eric Lippert, Heinz Gisslinger, Elisa Rumi, Thomas Lehmann, Christina A. Ortmann, Daniela Pietra, Cristiana Pascutto, Torsten Haferlach, Mario Cazzola Blood, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet Tiziano Barbui, Giovanni Barosi, Gunnar Birgegard, Francisco Cervantes, Guido Finazzi, Martin Griesshammer, Claire Harrison, Hans Carl Hasselbalch, Rudiger Hehlmann, Ronald Hoffman, Jean-Jacques Kiladjian, Nicolaus Kröger, Ruben Mesa, Mary F. McMullin, Animesh Pardanani, Francesco Passamonti, Alessandro M. Vannucchi, Andreas Reiter, Richard T. Silver, Srdan Verstovsek, Ayalew Tefferi Journal of Clinical Oncology, 2011
Management of myelofibrosis. Alessandro M. Vannucchi Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2011
What are RBC-transfusion-dependence and -independence? R.P. Gale, G. Barosi, T. Barbui, F. Cervantes, K. Dohner, B. Dupriez, V. Gupta, C. Harrison, R. Hoffman, J.-J. Kiladjian, R. Mesa, M.F. Mc Mullin, F. Passamonti, V. Ribrag, G. Roboz, G. Saglio, A. Vannucchi, S. Verstovsek Leukemia Research, 2011
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms Amy V. Jones, Peter J. Campbell, Philip A. Beer, Susanne Schnittger, Alessandro M. Vannucchi, Katerina Zoi, Melanie J. Percy, Mary Frances McMullin, Linda M. Scott, William Tapper, Richard T. Silver, David Oscier, Claire N. Harrison, Harald Grallert, Aliaksei Kisialiou, Paul Strike, Andrew J. Chase, Anthony R. Green, Nicholas C. P. Cross Blood, 2010
Evidence for organ-specific stem cell microenvironments Barbara Ghinassi, Fabrizio Martelli, Maria Verrucci, Emanuela D'Amore, Giovanni Migliaccio, Alessandro Maria Vannucchi, Ronald Hoffman, Anna Rita Migliaccio Journal of Cellular Physiology, 2010
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation for the GIMEMA Chronic Myeloproliferative Neoplasms Working Party, Valerio De Stefano, Tommaso Za, Elena Rossi, Alessandro M. Vannucchi, Marco Ruggeri, Elena Elli, Caterina Micò, Alessia Tieghi, Rossella R. Cacciola, Cristina Santoro, Nicola Vianelli, Paola Guglielmelli, Lisa Pieri, Francesca Scognamiglio, Emma Cacciola, Francesco Rodeghiero, Enrico M. Pogliani, Guido Finazzi, Luigi Gugliotta, Giuseppe Leone, Tiziano Barbui Annals of Hematology, 2010
Thrombosis in primary myelofibrosis: Incidence and risk factors Tiziano Barbui, Alessandra Carobbio, Francisco Cervantes, Alessandro M. Vannucchi, Paola Guglielmelli, Elisabetta Antonioli, Alberto Alvarez-Larrán, Alessandro Rambaldi, Guido Finazzi, Giovanni Barosi Blood, 2010
Increased differentiation of dermal mast cells in mice lacking the Mpl gene Barbara Ghinassi, Maria Zingariello, Fabrizio Martelli, Rodolfo Lorenzini, Alessandro M. Vannucchi, Rosa Alba Rana, Mitsuo Nishikawa, Giovanni Migliaccio, John Mascarenhas, Anna Rita Migliaccio Stem Cells and Development, 2009
Animal models of myelofibrosis Alessandro M. Vannucchi, Jean-Luc Villeval, Orianne Wagner-Ballon, Paola Guglielmelli, Anna Rita Migliaccio Source Book of Models for Biomedical Research, 2008
Thrombopoietin inhibits murine mast cell differentiation Fabrizio Martelli, Barbara Ghinassi, Rodolfo Lorenzini, Alessandro M. Vannucchi, Rosa Alba Rana, Mitsuo Nishikawa, Sandra Partamian, Giovanni Migliaccio, Anna Rita Migliaccio Stem Cells, 2008
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: A retrospective survey Marco Ruggeri, Francesco Rodeghiero, Alberto Tosetto, Giancarlo Castaman, Francesca Scognamiglio, Guido Finazzi, Federica Delaini, Caterina Micò, Alessandro M. Vannucchi, Elisabetta Antonioli, Valerio De Stefano, Tommaso Za, Luigi Gugliotta, Alessia Tieghi, Maria Gabriella Mazzucconi, Cristina Santoro, Tiziano Barbui Blood, 2008
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Alessandro M. Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro Rambaldi, Giovanni Barosi, Roberto Marchioli, Rosa Maria Marfisi, Guido Finazzi, Vittoria Guerini, Fabrizio Fabris, Maria Luigia Randi, Valerio De Stefano, Sabrina Caberlon, Agostino Tafuri, Marco Ruggeri, Giorgina Specchia, Vincenzo Liso, Edoardo Rossi, Enrico Pogliani, Luigi Gugliotta, Alberto Bosi, Tiziano Barbui Blood, 2007
Anaemia characterises patients with myelofibrosis harbouring Mpl W515L/K mutation Paola Guglielmelli, Alessandro Pancrazzi, Gaetano Bergamaschi, Vittorio Rosti, Laura Villani, Elisabetta Antonioli, Alberto Bosi, Giovanni Barosi, Alessandro M. Vannucchi, for the GIMEMA‐Italian Registry of Myelofibrosis, the MPD Research Consortium, Chicago, IL, USA British Journal of Haematology, 2007
Thrombocytosis and thrombosis. Alessandro M. Vannucchi, Tiziano Barbui Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2007
The haematocrit and platelet target in polycythemia vera Marcello Di Nisio, Tiziano Barbui, Leonardo Di Gennaro, Giovanna Borrelli, Guido Finazzi, Raffaele Landolfi, Giuseppe Leone, RosaMaria Marfisi, Ettore Porreca, Marco Ruggeri, Anne W. S. Rutjes, Gianni Tognoni, Alessandro M. Vannucchi, Roberto Marchioli, the European Collaboration on Low‐dose Aspirin in Polycythemia Vera (ECLAP) Investigators British Journal of Haematology, 2007
Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: A prospective study Haematologica, 2002
High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study Haematologica, 1997
Megakaryocyte-like increase in ploidy of Friend's erythroleukemia cells induced to endoreplication by colcemid Experimental Hematology, 1996
Detection of BCR/ABL transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation Haematologica, 1996
Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: A randomized trial Bone Marrow Transplantation, 1996
Cytokines and hemopoiesis: Laboratory diagnostic procedures Giornale Italiano Di Chimica Clinica, 1995
Circulating CFU-E during hematopoietic recovery after allogeneic bone marrow transplantation: Relationship to erythroid engraftment Experimental Hematology, 1995
Secondary allogenic bone marrow transplantation in acute leukemia: Experience in a single clinic Haematologica, 1994
Bone marrow transplantation with non-familial donors, experience in the bone marrow transplantation center of Florence Haematologica, 1994
Prostaglandin E2 in the treatment of cyclophosphamide-induced hemorrhagic cystitis in patients submitted to bone marrow transplantation Haematologica, 1994
Various therapeutic strategies for acute myeloid leukemia in first complete remission: Monocentric experience Haematologica, 1994
Monitoring of polyomavirus BK viruria in bone marrow transplantation patients by DNA hybridization assay and by polymerase chain reaction: An approach to assess the relationship between BK viruria and hemorrhagic cystitis Bone Marrow Transplantation, 1994
Activities of the bone marrow transplantation service of the hematology department of Florence: Report 3 Haematologica, 1994
Acetylcholinesterase in murine erythroleukemia (friend) cells: Evidence for megakaryocyte-like expression and potential growth-regulatory role of enzyme activity Blood, 1992
Constitutive expression of a megakaryocytic functional property by murine erythroleukemia (Friend) cells: The incorporation of serotonin Experimental Hematology, 1992
Recombinant human erythropoietin for treatment of myelodysplastic syndromes Leukemia, 1992
Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients Leukemia, 1992
The occurrence of infections and reinfections with herpes virus in subjects undergoing bone marrow transplantation, treated prophylactically with intravenous high doses of aciclovir Haematologica, 1992
Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation Bone Marrow Transplantation, 1991
Conventional treatment of essential thrombocytemia Haematologica, 1991
Quantitative platelet imaging and comparison of four mathematical models for the evaluation of placenta mean life span in patients with chronic immune thrombocytopenia Haematologica, 1991
Serum erythropoietin levels in allogeneic, non T-depleted bone marrow transplantation, and the effects of rhEpo administration Bone Marrow Transplantation, 1991
Inadequate erythropoietin production in allogeneic bone marrow transplant patients Haematologica, 1991
Early haemostatic modifications following cryopreserved graft infusion Bone Marrow Transplantation, 1991
In vivo stimulation of megakaryocytopoiesis by recombinant murine granulocyte-macrophage colony-stimulating factor Blood, 1990
